

## Research Article

## A Review Toxoplasmosis

Iddah, M. Ali

Department of Research and Department of Medical Laboratory, Alupe University, P.O. Box 845-50400, Busia, Kenya

\*Corresponding Author

Iddah, M. Ali

**Abstract:** *Toxoplasma gondii* is an intracellular protozoan infecting humans and animals. The term toxoplasmosis refers to the clinical or pathological disease caused by *Toxoplasma gondii* and *T. gondii* infection for an asymptomatic primary infection or persistence of the parasite in tissues. When considering toxoplasmosis in the differential diagnosis of a patient's illness, it is important to keep in mind that emphasis should not be placed on whether the patient has or has not been exposed to cats. Transmission of parasites essentially occurs without knowledge of the patient and may be unrelated to direct exposure to a cat (e.g., by ingestion of vegetables or water contaminated with oocysts or ingestion of undercooked meat contaminated with cysts). Serologic investigation of a cat to establish whether it is a potential source of the infection should be discouraged; the prevalence of *T. gondii* antibodies among cats in a given locale is usually similar to their prevalence in humans. Seropositivity in the cat does not predict shedding of oocysts. For clinical purposes, toxoplasmosis can be divided for convenience into five infection categories, including those (Abbasi *et al.*, 2003) acquired by immunocompetent patients, (Abgrall *et al.*, 2001) acquired during pregnancy, (Abgrall *et al.*, 2001) acquired congenitally; and (Afonso *et al.*, 2009) acquired by or reactivated in immunodeficient patients, and including (Afonso *et al.*, 2009; Windal, 2015) ocular infections. In any of the above mentioned categories, clinical presentations are not specific for toxoplasmosis, and a wide differential diagnosis must be considered. Furthermore, diagnostic methods and their interpretations may differ for each clinical classification.

**Keywords:** *Toxoplasma gondii*, Immunity, Protozoan, Seropositivity, immunocompetent.

## INTRODUCTION

Infection with the protozoan parasite *Toxoplasma gondii* has a worldwide distribution. This obligate intracellular parasite can infect humans as well as virtually all warm-blooded animals, including mammals and birds. Since its first description in the gundi, a rodent from North Africa, by Nicolle and Manceaux in 1908 (Nicolle & Manceaux, 1908), the parasite was progressively recognized as the agent of a widespread zoonosis. However, its entire life cycle was definitively understood only in the late 1960s (Dubey, *et al.*, 2002; Hutchison *et al.*, 1969), with the discovery of the central role of the cat as a definitive host harboring the sexual parasitic cycle and spreading oocysts through feces. In the same period of time, it was classified in the coccidian subclass (Frenkel *et al.*, 1970), phylum Apicomplexa, and the infectivity of the three parasitic stages (tachyzoite, cyst, and oocyst) was well characterized.

The true importance of toxoplasmosis in humans remained unknown until the first reports of cases of congenital toxoplasmosis (Schwartzman *et al.*, 1948). The history of clinical toxoplasmosis and the wide spectrum of this disease revealed over the years were reviewed by Weiss and Dubey in 2009 (Weiss & Dubey, 2009). The growing role of *Toxoplasma* infection in immunocompromised patients was acknowledged in the mid-1970s, and the concept of the reactivation of infection was thereafter extensively explored by immunologists. During the last decade, the development of new genotyping tools and the multiplication of field studies have led to breakthroughs in the comprehension of the phylogenetic evolution of *T. gondii* in the world (Mercier *et al.*, 2011), and recent advances in our knowledge of the particular virulences associated with some genotypes have been achieved (Saeij *et al.*, 2007). This review will cover information on toxoplasmosis, epidemiology, diagnostic and parasite genotypes.

Quick Response Code



Journal homepage:

<http://www.easpublisher.com/easjbg/>

Article History

Received: 15.06.2019

Accepted: 15.07.2019

Published: 30.07.2019

**Copyright © 2019 The Author(s):** This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY-NC 4.0) which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the original author and source are credited.

DOI: 10.36349/easjbg.2019.v01i04.002

## BIOLOGY OF THE PARASITE

### Three Parasitic Stages

There are three infective stages of *T. gondii*: a rapidly dividing invasive tachyzoite, a slowly dividing bradyzoite in tissue cysts, and an environmental stage, the sporozoite, protected inside an oocyst. These infective stages crescent-shaped cells, approximately 5 µm long and 2µm wide, with a pointed apical end and a rounded posterior end. They are limited by a complex membrane, named the pellicle, closely associated with a cytoskeleton involved in the structural integrity and motility of the cell. They possess a nucleus, a mitochondrion, a Golgi complex, ribosomes, an endoplasmic reticulum, and a multiple-membrane-bound plastid-like organelle called the apicoplast, the result of a possible acquisition by the parasite via a secondary endosymbiosis of a free-living red alga (Roos *et al.*, 1999). As for other members of the phylum Apicomplexa, they concentrate in their apical part a specialized cytoskeletal structure (the conoid, involved in cell invasion) and numerous secretory organelles (rhoptries [ROPs], dense granules, and micronemes). More details were reported elsewhere previously (Henriquez, 2008; Dubey *et al.*, 1998; Weiss & Kim, 2007).

Tachyzoites are the dissemination form. They are able to invade virtually all vertebrate cell types, where they multiply in a parasitophorous vacuole. Bradyzoites result from the conversion of tachyzoites into a slow-dividing stage and form tissue cysts. These cysts are more or less spheroid in brain cells or elongated in muscular cells. They vary in size from 10 µm for the younger cysts, containing only two bradyzoites, to up to 100 µm for the older ones, containing hundreds or thousands of densely packed bradyzoites. The cyst wall consists of a limiting membrane presenting numerous invaginations and an underlying layer of electron-dense granular material (Ferguson, 2004). Bradyzoites have a latent metabolism, well adapted to long-term survival. Cysts remain intracellular throughout their life span. The death of the host cell may trigger the disruption of the cyst wall and the consequent liberation of bradyzoites. The resistance of bradyzoites to the acid pepsin (1- to 2-h survival into pepsin-HCl) allows their transmission through ingestion.

Sporozoites are located in mature oocysts. Oocysts are 12- to 13-µm ovoid structures that after sporulation contain two sporocysts, each containing four sporozoites. The oocyst wall is an extremely robust multilayer structure protecting the parasite from mechanical and chemical damages. It enables the parasite to survive for long periods, up to more than a year, in a moist environment (Mai *et al.*, 2009).

### Life Cycle of *T. gondii*

*T. gondii* is a tissue-cyst-forming coccidium functioning in a prey- predator system that alternates between definitive (sexual reproduction) and intermediate (asexual replication) hosts. It is unique among this group because it can be transmitted not only between intermediate and definitive hosts (sexual cycle) but also between intermediate hosts via carnivorism (asexual cycle) or even between definitive hosts. The parts of the sexual and asexual cycles and transmission dynamics in a given environment vary according to physical characteristics and according to the structures of Sexual reproduction occurs only in felids (domestic and wild cats). After the ingestion of cysts present in tissues of an intermediate host, the cyst wall is destroyed by gastric enzymes. Bradyzoites settle within enterocytes, where they undergo a self-limiting number of asexual multiplications, characterized by the development of merozoites within schizonts (Dubey, 1998). This first step is followed by sexual development, with the formation of male and female gametes (gametogony) (Ferguson, 2002). After fertilization, oocysts formed within enterocytes are liberated by the disruption of the cell and excreted as unsporulated forms in cat feces. The process of sporogony occurs after a few days in the external environment. It implies a meiotic reduction and morphological changes leading to the formation of a sporulated oocyst with two sporocysts, each containing four haploid sporozoites. The shedding of oocysts begins 3 to 7 days after the ingestion of tissue cysts and may continue for up to 20 days. Infected cats can shed more than 100 million oocysts in their feces (Dubey & Frenkel, 1972, Jones & Dubey, 2010). They can infect a wide range of intermediate hosts, virtually all warm-blooded animals, from mammals to birds, when ingested with food or water. Oocysts are also infective for cats although less efficiently.

Within intermediate hosts, the parasite undergoes only asexual development. After oocyst ingestion, sporozoites are liberated. They penetrate the intestinal epithelium, where they differentiate into tachyzoites. Tachyzoites rapidly replicate by endodyogeny both intermediate and definitive host populations (Afonso, *et al.*, 2009). Inside any kind of cell and disseminate throughout the organism. As a result of the conversion from tachyzoite to bradyzoite, tissue cysts arise as early as 7 to 10 days postinfection and may remain throughout life in most hosts, predominantly in the brain or musculature.

Upon the ingestion of these tissue cysts by an intermediate host through raw or undercooked meat, cysts are ruptured as they pass through the digestive tract, causing the release of bradyzoites. The bradyzoites will infect the intestinal epithelium of the new host and differentiate back into the rapidly dividing tachyzoite stage for dissemination throughout the body. In addition, if the acute phase occurs during pregnancy,

the parasite can cross the placenta and infect the fetus (congenital transmission). A role for this vertical transmission in maintaining high levels of infection in some species has been suggested (Duncanson *et al.*, 2001).

### Mechanism of Cell Invasion

*T. gondii* is remarkable in its ability to invade a wide variety of host cells. Invasion is an active process relying on parasite motility and the sequential secretion of proteins from secretory organelles, the micronemes, the rhoptries, and the dense granules.

Attachment to the host cell membrane is a prerequisite for invasion. It requires the calcium-dependent secretion of adhesins from micronemes, such as the microneme protein MIC2, which recognize host cell receptors and promote parasite reorientation and attachment. Cell invasion relies on a complex interaction between the host cell surface and the parasite, a process called gliding motility, an intricate linear motor system promoted by actinmyosin interactions and dynamic rearrangements of the parasite cytoskeleton (Carruthers & Boothroyd, 2007). Entry is a rapid process (15 to 30 s) distinct from currently known host endocytic events. *Toxoplasma* forms a tight association between its apical end and the host cell membrane, called the moving junction. This moving junction moves from the apical end to the posterior end of the parasite, leading to the internalization of the parasite into a parasitophorous vacuole (PV). The establishment of this moving junction around the invading parasite requires the distribution over the entire surface of the parasite of an apical membrane antigen (AMA1), also secreted by micronemes, and the secretion of rhoptry (ROP) neck proteins (RONs) inserted into the host cell membrane (Dubremetz, 2007). The formation of the nascent parasitophorous vacuole membrane (PVM) requires the secretion of proteins from the ROPs. In recent years, a major role for the ROP2 family proteins has been recognized. Of these proteins, ROP18 is associated with the cytosolic face of the PVM and exerts protein kinase activity, which has a profound effect on parasite growth and virulence (El Hajj *et al.*, 2007), and ROP16 is able to manipulate host gene expression, affecting interleukin secretion (Laliberte & Carruthers, 2008).

Besides ROP proteins, dense granular proteins also contribute to the formation of the PVM during the first hour following invasion. Most host transmembrane proteins are stripped from the PVM during the invasion process; this process modifies biochemical characteristics of the PVM and prevents fusion with lysosomes or any cytoplasmic vesicle. Dense-granule secretions also support the development of a complex network of membrane tubules that develop from the PVM and extend into the vacuolar lumen (Mercier *et al.*, 2005). This network is supposed to have a role in developing exchanges between the parasite and the host

cell, bringing in nutrients from the host cell cytosol or exporting proteins or lipids from the parasite toward the PVM or the host cell. The PVM is also closely associated with host cell mitochondria, which contribute to parasite metabolism. Within the PV, tachyzoites divide during a 6- to 9-h cycle, by a process of endodyogeny, leading to the formation of two daughter cells within each mother cell. They exit the cell usually after 64 to 128 parasites have accumulated in the PV (Black & Boothroyd, 2000). Egress from the cell is an active process dependent upon a rise in the calcium concentration after the release from intracellular stores (Sibley, 2010).

### PREVALENCE AND IMPORTANCE OF TOXOPLASMOSIS IN THE WORLD

#### Prevalence of Infection in Humans

It is generally assumed that approximately 25 to 30% of the world's human population is infected by *Toxoplasma* (Montoya & Liesenfeld, 2004). Actually, the prevalences vary widely between countries (from 10 to 80%) and often within a given country or between different communities in the same region (Pappas *et al.*, 2009). Low seroprevalences (10 to 30%) have been observed in North America, in South East Asia, in Northern Europe, and in Sahelian countries of Africa. Moderate prevalences (30 to 50%) have been found in countries of Central and Southern Europe, and high prevalences have been found Latin America and in tropical African countries.

As for animals, many factors can affect seroprevalence in humans. Climatic factors affecting the survival of oocysts in the environment and, hence, infection rates in meat-producing animals play a major role. Higher prevalences are classically observed for tropical countries with a humid and warm climate, and conversely, lower prevalences are found for arid countries or for colder countries, but anthropogenic factors explain a large part of the variations in human seroprevalence, including dietary habits (method of cooking meat, hand washing, kinds of meat or vegetables consumed, and vegetable cleaning, etc.); economic, social, or cultural habits; quality of water; and sanitation coverage. Seroprevalence increases with age, but the rate of acquisition of infection in relation to age varies according to the country and socioeconomic level. Near-maximal seroprevalence may be reached in childhood in populations living under poor-hygiene conditions, probably linked to telluric or waterborne contamination by oocyst ingestion. This points toward water as an important source of human infection in areas where humans use unfiltered surface water for consumption and probably also in areas where there is contact with freshwater, for instance, for recreation (Ertug *et al.*, 2005; Jones & Dubey, 2010). As an example, in a city located in the northern Rio de Janeiro state (Brazil), the age-adjusted seroprevalence was 84% for the group of the lower socioeconomic level, compared to seroprevalences of 62% and 23% for

the groups of the middle and upper socioeconomic levels, respectively (Bahia-Oliveira *et al.*, 2003). Most persons (up to 84%) in the population of the lower socioeconomic level were infected by the age of 15 years, whereas infection was acquired mostly after the age of 20 years in the population of the upper socioeconomic level (from about 20% for the age group of 20 to 29 years to 70% for the age group of 40 to 49 years). In a multivariate risk factor analysis, this was attributed to differences in water supply, with the poorest populations living in areas supplied with unfiltered water. These different patterns of Toxoplasma acquisition according to socioeconomic levels may be more relevant in underdeveloped tropical countries, but in the United States, Toxoplasma infection was also considered an infection associated with poverty (Hotez, 2008). The overall seroprevalence (U.S. and foreign-born individuals combined) was higher among non-Hispanic black persons and Mexican Americans than among non-Hispanic white persons (Jones *et al.*, 2007). Logically, increased socioeconomic levels, together with an improvement of hygienic conditions, changes in farming systems, the consumption of frozen meat, and the feeding of cats with sterilized food, have led to a continuous decrease of the seroprevalence in most industrialized countries over the last decades. In the United States, a national survey found a decrease in the age-adjusted *T. gondii* prevalence in U.S.-born persons aged 12 to 49 years, from 14.1% in 1988 to 1994 to 9% in 1999 to 2004 (Jones *et al.*, 2007). In France, the seroprevalences in pregnant women were about 80% in the early 1960s, around 66% in the 1980s, 54% in 1995, and 44% in 2003, while at the same time, the average age of pregnant women increased (Villena *et al.*, 2010). This declining seroprevalence has been observed in all areas where it was studied in Europe. For example, in The Netherlands, the seroprevalence decreased from 35.2% in 1995 to 1996 to 18.5% in 2006 to 2007 in women of reproductive age (Hofhuis *et al.*, 2011).

#### HOW DO HUMANS BECOME INFECTED?

The majority of horizontal transmissions to humans is caused either by the ingestion of tissue cysts in infected meat or by the ingestion of soil, water, or food contaminated with sporulated oocysts derived from the environment or, less frequently, directly from feline feces. The relative importance of transmissions via tissue cysts versus oocysts in a given population is unknown, except in the case of outbreaks with a well-defined source of infection. Until now, only risk factor studies gave an indication of the predominant route of transmission in a given population. However, in these epidemiological studies, risk factors for infection remained unexplained in 14 to 49% of cases (Cook *et al.*, 2000, Jones, *et al.*, 2009). Persons may be unaware of their exposure or may have difficulty recalling specific risks that occurred. The recent discovery of a sporozoite or oocyst-specific protein, which elicited antibody production and differentiated oocyst- versus

tissue cyst-induced experimental infection in pigs and mice, may help to solve this problem (Hill *et al.*, 2011). Serum antibodies to the sporozoite protein were detected in humans within 6 to 8 months of an initial oocyst-acquired infection. Therefore, this serological assay could be useful for detecting exposure to oocysts in the early months after *T. gondii* infection and could be useful for epidemiological studies.

#### Infection through Cysts

Consumption of meat (i) Type of meat. Any meat from warm-blooded animals and birds has been traditionally considered a major source of Toxoplasma infection in Western countries. The risk associated with the type of meat (lamb, pork, and beef, etc.) varies among different countries according to local eating habits and according to the prevalence in meat-producing animals. In a multicenter study in Europe, meat consumption was estimated to be responsible for 30 to 63% of cases of infection, while soil contact represented 6 to 17% of cases (Cook *et al.*, 2000). In the United States, a recent case-control study showed an elevated risk for *T. gondii* infection in persons eating raw ground beef (adjusted odds ratio [aOR], 6.67; attributable risk [AR], 7%); eating rare lamb (aOR, 8.39; AR, 20%); eating locally produced cured, dried, or smoked meat (aOR, 1.97; AR, 22%); or working with meat (aOR, 3.15; AR, 5%) (Jones, *et al.*, 2009). Outbreaks due to the consumption of undercooked meat have been described. These outbreaks generally involved only a few patients (2 to 20 persons) (Windal, 2015).

A quantitative assessment of the risk of Toxoplasma in food for consumers is hampered by the lack of data on the number of tissue cysts resulting in infection of humans, the distribution and the number of cysts in the different muscle sites in various hosts, as well as their infectivity in commercial meat products. One recent survey of meat from commercial markets (pork, chicken, and beef) in the United States suggested a low risk, perhaps owing to meat treatment processes, which could reduce the viability of cysts (Dubey *et al.*, 2005). This may not be the case in countries where lamb and sheep are the most consumed meats (Berger *et al.*, 2009, 162).

(ii) Cyst resistance. Tissue cysts remain infectious in refrigerated carcasses (1°C to 6°C) or minced meat for up to 3 weeks. Freezing alone is not a reliable means of rendering all tissue cysts noninfective: cysts have remained viable for >11 days at -7°C. However, the deep-freezing of meat at -12°C or lower for at least 3 days is usually efficacious to kill cysts, although it may depend on the thickness of the piece of meat (Dubey, 1988).

Tissue cysts are usually killed immediately by heating to 67°C. The survival of tissue cysts at lower

temperatures depends on the duration of cooking. Tissue cysts remain viable at 60°C for about 4 min and at 50°C for about 10 min (Dubey *et al.*, 1990). Cooking for a prolonged period of time may be necessary under household conditions to achieve the temperatures that are required to kill all tissue cysts of *Toxoplasma* in all parts of the meat. Some tissue cysts will remain infectious after cooking in a microwave oven, possibly due to an uneven heating of the meat. However, in a U.S. case-control study (Jones *et al.*, 2009), microwave cooking of meat was associated with a reduced risk of recent *T. gondii* infection. This was explained by the fact that microwave cooking is often associated with reheating already-cooked meat or with defrosting or cooking frozen meat.

Commercial procedures of curing with salt, sucrose, or low-temperature smoking may kill tissue cysts, but the survival time of tissue cysts varies greatly with the concentration of the salt solution and the temperature of storage. Salting does not necessarily kill tissue cysts in homemade pork sausages. Under laboratory conditions, solutions containing 2% sodium chloride or 1.4% potassium or sodium lactate are effective within 8 h of injection for the killing of *T. gondii* tissue cysts in pork loin (Hill *et al.*, 2006). Other food treatment processes, such as gamma irradiation at a dose of 1.0 kGy and high pressure (300 mPa), were found to be efficient for killing tissue cysts in meat, but some treatment procedures are barely applicable for meat destined for human consumption (Lindsay *et al.*, 2006).

Infection related to solid-organ transplantation. As *T. gondii* tachyzoites can invade all nucleated cells, cysts can be found in virtually any organ. Therefore, in solid-organ transplantation (SOT), *Toxoplasma* infection can be transmitted through a cyst-containing organ from a donor (D) with infection acquired in the distant past to a nonimmunized recipient (R). However, certain organs are more likely to harbor persistent cysts than others. Muscles commonly sustain parasite encystment; thus, heart transplant patients are at a higher risk for organ-related toxoplasmosis than are liver, lung, or kidney transplant patients. Toxoplasmosis was recognized early as an infectious complication in heart transplant patients (Ryning *et al.*, 1979), which motivated the implementation of large retrospective studies in several countries from 1980 onwards. However, the incidence of acquired toxoplasmosis in case of a mismatch (D+/R-) is variable, since it depends largely on the prevalence of toxoplasmosis in the country of study and on the use of chemoprophylaxis after transplantation. In retrospective studies, the incidence can vary from 9 to 56% when the patients benefit or not from a chemoprophylaxis scheme, respectively, indicating that prevention is efficient. In a recent multicenter retrospective study including 22 patients with acquired toxoplasmosis within a median time of 92 days post transplantation,

mismatched transplants were documented for 9 patients, and the donor's serology was unknown for 8 other negative recipients (Fernandez-Sabe N, *et al.*, 2011). Twelve of 22 cases were heart transplant patients. The incidence of donor acquired toxoplasmosis is less frequent in other SOT patients, and only 9 and 16 cases were reported for liver and kidney mismatched patients, respectively, supported by solid serologic evidence. A case of disseminated toxoplasmosis following small bowel transplantation was also described, but the serostatus of the donor was unknown, making the source of infection uncertain (Campbell *et al.*, 2006).

Infection through Oocysts Survival of oocysts in the environment. As highlighted by previous epidemiological studies, environmental conditions are important for oocyst survival. Moist conditions can increase oocyst survival during long periods of heat, which likely accounts for the high prevalences in tropical countries of South America and Africa. In Colombia, a correlation was found between the mean amount of rainfall and the incidence of congenital toxoplasmosis (Gomez-Marin *et al.*, 2011). Even in a country with a temperate climate, such as France, the risk of infection in cats was shown to increase when the weather was both warm and moist, or moderate and less moist, reflecting the influence of climatic conditions on the prey population and oocyst survival (Abgrall *et al.*, 2001).

Despite the low prevalence (<1% in most studies) and short duration of oocyst shedding by cats, the burden in the environment may be very high (Dabritz *et al.*, 2007). A single cat may shed more than 100 million oocysts, which are nonsporulated. These oocysts need between 1 and 5 days to mature and become infective for other hosts, which explains why direct contact with cats is not thought to be a major risk for human infection. In the United States, an increased risk associated with exposure to kittens was limited to respondents who had 3 or more kittens, thus more likely to be infected through the shedding of oocysts after primary infection (Jones *et al.*, 2009). Oocysts are able to sporulate within 2 to 3 days in different types of commercial cat litter and occasionally remain viable for 14 days (Dubey *et al.*, 2011). Unsporulated oocysts lose their capacity to sporulate, and, hence, to become infective, after freezing at -6°C during 7 days or after exposure to 37°C for 1 day. Once sporulated, oocysts are resistant to harsh environmental conditions. They remain viable in a moist environment for more than a year. Under laboratory conditions, sporulated oocysts can survive storage at 4°C for up to 54 months. They survive freezing at -10°C for 106 days and heating at 35°C and 40°C for 32 days and 9 days, respectively. However, they are killed within 1 to 2 min by heating to 55°C to 60°C (Dubey, 2010), conditions easily obtained when cooking vegetables. The wall of sporulated oocysts is highly impermeable and, there-

fore, very resistant to disinfectants (Dumetre & Darde, 2003).

Contamination of water. Oocysts can remain viable for long periods of time in water and can resist freezing and moderately high water temperatures. They are not killed by chemical and physical treatments currently applied in water treatment plants, including chlorination and ozone treatment (Dumetre *et al.*, 2008). Outbreaks associated with the contamination of reservoirs supplying water, such as those described for the Greater Victoria area of British Columbia, Canada (Aramini *et al.*, 1999); in Santa Isabel do Ivaí, Brazil (De Moura *et al.*, 2006); or in Coimbatore, India (Balasundaram *et al.*, 2010), involved a large number of patients. The epidemics were preceded by peaks of heavy rainfall and turbidity in the implicated reservoirs. Smaller epidemics were described after the drinking of raw surface water in remote tropical areas (Benenson *et al.*, 1982; Demar *et al.*, 2007). Freshwater runoff from urban centers next to seashores may contaminate seawater. Toxoplasma oocysts can remain viable for extended periods of time in seawater (Lindsay & Dubey, 2009). Shellfish are filter feeders that concentrate *T. gondii*. Oocysts remained viable and were detected in various species of shellfish under natural conditions (Esmerini *et al.*, 2010; Miller *et al.*, 2008; Putignani *et al.*, 2011). The consumption of oysters, clams, and mussels has been shown to be a risk factor for acquiring Toxoplasma infection in the United States (Jones *et al.*, 2009).

The detection of Toxoplasma in water is difficult, and no standardized methods are available. The methodology is based on the experience gained from other coccidians, such as Cryptosporidium, and involves the concentration of oocysts using centrifugation, filtration, immunomagnetic separation, or flocculation of large volumes of water (Dumetre & Darde, 2007; Shapiro *et al.*, 2010). Different PCR methods have been proposed (Sotiriadou & Karanis, 2008). In France, a survey found Toxoplasma DNA in 7% of raw surface water samples. Well water was PCR positive in 9% of samples in this French study (Villena *et al.*, 2004) and also in 13 to 27% of samples in Poland, depending on the depth of the well (Sroka *et al.*, 2010). A positive correlation was observed between the consumption of unboiled well water and the presence of Toxoplasma antibodies, especially for farms with poor-hygiene conditions surrounding shallow wells.

Contamination of soil, vegetables, and fruits. Contact with soil was identified as a strong risk factor in a European multicenter case-control study, and 6 to 17% of primary infections in humans were attributed to this risk factor (Cook *et al.*, 2000). A U.S. study showed that the detection of antibodies against Toxoplasma was 2-fold higher in a population with positive Toxocara antibodies, suggesting a common

exposure to contaminated soil (Jones *et al.*, 2008). The risk of acquiring Toxoplasma infection after soil contact or ingestion is particularly high for children. Toxoplasma oocysts were isolated in as many as 32% of school play grounds in a Brazilian study (Dos Santos *et al.*, 2010).

Contaminated water and soil may act as vehicles for the transfer of oocysts to vegetables and fruit for human consumption, although there are few data available to confirm this. In several risk factor or case-control studies, the eating of unwashed raw vegetables or fruits was associated with an increased risk of primary infection (Berger *et al.*, 2009; Kapperud *et al.*, 1996; Liu *et al.*, 2009). Experimentally, *T. gondii* oocysts can adhere to berries, especially raspberries, and can be recovered by bioassays in mice (Kniel *et al.*, 2002), but there has been no report of the detection of Toxoplasma on fruits or vegetables under nonexperimental conditions.

### Infection through Tachyzoites

Food-borne contamination. Outside its host cell, the tachyzoite is a fragile stage, easily destroyed by digestive enzymes (10-min survival in pepsin-HCl). It is also very sensitive to environmental conditions and is usually killed rapidly outside the host. Therefore, the horizontal transmission of Toxoplasma via tachyzoites is probably not important from an epidemiological point of view. However, tachyzoites were suggested to be the cause of rare cases of acquired toxoplasmosis in humans after the consumption of unpasteurized goat's milk (Tenter *et al.*, 2000). The drinking of unpasteurized goat's milk was found to be a risk factor in an epidemiological survey (Jones *et al.*, 2009), suggesting that tachyzoites may enter the host by the penetration of mucosal tissue.

Congenital infection. When primary infection is acquired by a pregnant woman, tachyzoites can colonize placental tissues during the dissemination process and from there can gain access to the fetal compartment in about 30% of cases. The frequency of vertical transmission increases with the gestational age at maternal infection. At the beginning of pregnancy, the transplacental passage of tachyzoites is a rare event, but the consequences for the offspring are heavy. The immune control of placental infection is probably a key event in the occurrence of congenital infection (Pfaff *et al.*, 2007), but advances in the comprehension of the pathophysiological process remain to be achieved. Congenital infection is the most important part of the disease burden due to Toxoplasma infection in humans. Clinical manifestations of congenital toxoplasmosis first motivated research on the parasite and its pathophysiology and epidemiology. However, the factors influencing congenital transmission are still poorly known, apart from the term of pregnancy at the time of maternal infection and, of course, the immune status of the mother.

The observation of a decreasing seroprevalence of toxoplasmosis in industrialized countries has complex consequences for the risk of acquisition of *Toxoplasma* infection during pregnancy. At first glance, a reduced seroprevalence increases the percentage of pregnant women susceptible to primary infection and, hence, to congenital transmission to their fetuses. However, the lower level of circulation of the parasite in the environment diminishes the global risk of acquiring infection during pregnancy. A national surveillance system was implemented in France in 2007, which aims to collect data from all cases of congenital toxoplasmosis through data transmitted by laboratories certified for prenatal diagnosis or implicated in neonatal serological diagnoses. This network reported 272 cases of congenital toxoplasmosis in 2007 (Villena *et al.*, 2010). If these data can be considered exhaustive, they can allow an evaluation of the overall prevalence of congenital toxoplasmosis in France, 3.3 per 10,000 live births (Villena *et al.*, 2010), which is nearly the prevalence reported in Brazil (1 per 3,000 live births) (Neto *et al.*, 2000) but 3-fold higher than that estimated in a pilot study in Massachusetts (1 per 10,000 live births) (Guerina *et al.*, 1994).

**Transmission through injection.** Fourteen cases of laboratory contamination of a parenteral origin have been described (Herwaldt, 2001). Most cases were attributed to needlestick injuries or scratching while manipulating tachyzoites from the RH strain.

The risk of transmitting infection through a blood transfusion is theoretically possible if the donor has recently acquired a *Toxoplasma* infection and is parasitemic at the time of blood sampling. Similarly, a risk associated with bone marrow is possible if the donor is parasitemic at the time of collection. However, the maximal duration of dissemination of tachyzoites through the blood flow is barely known for humans; it may depend on the parasite strain and on the host immune response. Parasite DNA was detected in 9 out of 17 patients during 5 weeks following acute toxoplasmosis with lymphadenopathy (Guy & Joynson, 1995). In a mouse model, it was also shown by PCR that parasitemia was detected during 3 weeks after oral infection (Paugam *et al.*, 1995).

## POPULATION STRUCTURE OF *T. GONDII* Genotypes and Their Geographic Distribution

Studies of genotypes of *T. gondii* began in the early 1990s and at first relied on isoenzyme analysis (Darde *et al.*, 1992, Darde *et al.*, 1988) and on a few PCR-restriction fragment length polymorphism (RFLP) markers (Howe & Sibley, 1995). Genotyping was later refined by the addition of new PCR-RFLP markers (Zhang & Dubey, 2006) and by microsatellite analysis (Ajzenberg *et al.*, 2010, Ajzenberg *et al.*, 2005). The sequencing of selectively neutral introns was proposed to be a better tool for phylogenetic studies (Khan *et al.*,

2007), whereas microsatellites are better adapted to population genetic structure and outbreak investigations (Demar *et al.*, 2007; Mercier *et al.*, 2010; Weiss & Dubey, 2009).

Despite the presence of a sexual cycle and a worldwide distribution, the population structure of this parasite was initially described as being highly clonal and exhibiting a low genetic diversity. This was the conclusion of genetic studies of isolates from Europe and the United States, which grouped these isolates into three major multilocus genotypes, types I, II, and III, equivalent to clonal lineages, stable in time and space (Ajzenberg *et al.*, 2002; Darde *et al.*, 1992; Darde *et al.*, 1988; Howe & Sibley, 1995; Sibley & Boothroyd, 1992). This simple clonal structure is accompanied by a low level of genetic divergence among the three lineages. However, multilocus and multichromosome genotyping of isolates from other continents revealed a much more complex population structure with a greater genetic diversity, likely reflecting a history of more frequent genetic exchanges and genetic drift (Ajzenberg *et al.*, 2004; Lehmann, *et al.*, 2004). The majority of isolates from South America, Africa, or Asia do not fit into the three major lineages. The clustering of these genotypes led to the description of new haplogroups, some of them largely distributed over continents, being considered other successful clonal lineages (Mercier *et al.*, 2010; Pena *et al.*, 2008). Ongoing efforts are aimed at gathering data from analyses with different markers (PCR-RFLP, microsatellites, and sequencing of introns) to establish a consensus nomenclature for these haplogroups, which may be useful for basic biology as well as for clinical studies. Up to now, 12 haplogroups (including the 3 initially described lineages, types I, II, and III) have been described (Khan *et al.*, 2011; Khan *et al.*, 2007), based on sequence-based analyses, but these haplogroups are not totally homogenous, and more resolutive markers revealed sub clustering that may be associated with geographical origins and phenotypic characteristics. There still remain truly atypical and highly diverse isolates with many unique polymorphisms which cannot be clustered into one of these haplogroups (Mercier *et al.*, 2011).

From Northern Europe (Jokelainen *et al.*, 2011) to Southern Europe (De Sousa *et al.*, 2006), the population structure of *T. gondii* is markedly clonal, with a pre-dominance of strains belonging to the type II lineage. In France, type II strains represent more than 90% of isolates from both humans and animals (Ajzenberg *et al.*, 2002; Aubert *et al.*, 2010, Halos *et al.*, 2010). Two other clonal lineages are occasionally (type III) or exceptionally (type I) found in Europe. Type III may be more frequently encountered in Southern Europe (Waap *et al.*, 2008). The isolation of atypical strains which do not fit into these 3 major lineages is rare in Europe and likely suggests contamination by non-European strains either during residence abroad or after the consumption of imported

food (Dardé *et al.*, 2007; Pomares *et al.*, 2011). In North America, the population structure appeared similar to that observed in Europe, with a predominance of type II strains (Howe & Sibley, 1995), but recent data suggest a higher prevalence of atypical strains in North America in wild as well as in domestic animals (Dubey *et al.*, 2008) and another clonal haplogroup (haplogroup 12) close to type II (Khan *et al.*, 2011). South America is an area with a high level of diversity for *T. gondii*. Although additional clonal lineages, known as the Br I to IV haplogroups, may be common and endemic in Brazil, it is clear that frequent genetic exchanges have generated a wide variety of different genotypes (Pena *et al.*, 2008). Eighty-eight genotypes (defined with 11 PCR-RFLP markers) have already been identified from a variety of animal hosts in Brazil, and new genotypes are continuously being identified in different animal species, indicating an extremely high level of diversity of *T. gondii* in the population (Pena *et al.*, 2011), whereas type II seems to be very rare in South America (Dubey *et al.*, 2006). The high level of genetic diversity observed in this continent is maximal in the wild Amazonian area, with many unique polymorphisms (Ajzenberg *et al.*, 2004). In an Amazonian country such as French Guiana, the interpenetration of anthropized and wild rainforest environments leads to hybridization between strains that may represent a potential risk for human health (Mercier *et al.*, 2011). In Africa, a clonal population structure consisting of additional common clonal lineages known as the Africa 1 to 3 haplogroups, coexisting with type II and III lineages, has been described (Velmurugan *et al.*, 2008). In Asia, the first reports from China, Sri Lanka, and Vietnam (Dubey *et al.*, 2007) revealed a more limited genetic diversity than in South America, with some genotypes being common to both areas. In China, a clonal lineage seems to be widespread across the country (Zhou *et al.*, 2010).

### Genotypes and Virulence

Experimental virulence is usually defined with the mouse model after the intraperitoneal inoculation of a given number of tachyzoites. Type I isolates are highly virulent, leading to the death of mice less than 10 days after the inoculation of <10 tachyzoites, while type II or III strains are considered avirulent strains, allowing survival after the inoculation of >103 tachyzoites. Isolates from other clonal lineages or from atypical strains range from the highly virulent to the intermediate or non-virulent phenotype, according to differences in the combination of genes that they have inherited (Darde, 2008; Grigg & Suzuki, 2003). Genotypes with a majority of type I alleles are usually more virulent (Mercier *et al.*, 2010).

The mouse-virulent strains display several characteristics that may explain the rapid dissemination of the parasite and the higher tissue burden observed for mice and other susceptible hosts: enhanced migration across polarized epithelia or across the extracellular

matrix, higher rates of the ex vivo penetration of the lamina propria and submucosa (Barragan & Sibley; 2002), and, in cell culture, higher growth rates and lower rates of interconversion from tachyzoites to bradyzoites (Saeij *et al.*, 2005). Experimental crosses between strains with different virulence patterns facilitated the identification of several poly morphic genes coding for secreted factors of *Toxoplasma* associated with differences in the expression of virulence in mice (Reese *et al.*, 2011; Saeij *et al.*, 2006, Taylor *et al.*, 2006). These key virulence factors are secretory proteins discharged from apical organelles, the rhoptries. The proteins of this rhoptry family (ROP5, ROP16, and ROP18) exert kinase or pseudokinase activity. They are injected directly into the host cell and play a role during the process of parasite invasion or in the induction of interleukin-12 (IL-12) secretion by mouse macrophages (Robben *et al.*, 2004). Although these biological and genetic data demonstrate the different intrinsic properties of the different strains, the expression of this virulence in a given host species is a more complex trait which depends on several host and parasite characteristics. Different host species are more or less susceptible. The genetic background of a given species, as demonstrated for different mouse or rat strains, may also influence the expression of virulence (Cavaillès *et al.*, 2006).

The expression of virulence in humans is a complex phenomenon due to many other factors that could influence the pathogenicity of a given strain: other parasitic factors (infectious stage and inoculum), the genetic background of the host, and overall immune status (Maubon *et al.*, 2008). *Toxoplasma gondii* is usually considered an opportunistic parasite in humans, and any analysis of the relationship between genotype and pathogenicity should consider these different factors. This explains why the role of the strain is still a matter of debate, especially when the host is immunocompromised. Strains isolated from patients are mainly the strains circulating in a given country, and the same type of strain can be responsible for different outcomes. For example, type II strains were involved in 96% of consecutive cases of congenital toxoplasmosis in France (Ajzenberg *et al.*, 2002), in 85% of immunocompromised patients who acquired *Toxoplasma* infection in Europe (Dardé *et al.*, 2007), and in 73% of cases of ocular disease in France (Fekkar *et al.*, 2011). In immunocompromised patients, the conclusion of a study of 85 patients (HIV and non-HIV immunodeficient patients) was that the genotype of the infecting strain had no influence on the clinical manifestation (cerebral or extracerebral) or clinical outcome (Dardé *et al.*, 2007), indicating that immune status is responsible for virulence expression in these patients.

However, several direct and indirect arguments plead for an influence of the strain on clinical severity. In immunocompetent patients, severe toxoplasmoses



with multiorgan failure were linked to atypical strains acquired from the Amazonian rainforest (Carme *et al.*, 2002). Occasional reports of such severe cases due to atypical strains have come from other countries (De Salvador-Guillouet *et al.*, 2006), sometimes after the consumption of infected food (Pomares *et al.*, 2011). The high rate of occurrence of acquired ocular toxoplasmosis in Southern Brazil (21% in individuals over 13 years of age) has been attributed to the genotypes circulating in this region (De-la-Torre *et al.*, 2007; Khan *et al.*, 2006). In cases of congenital toxoplasmosis, the strain was likely to play a role in the different outcomes observed by a comparative prospective cohort study of congenitally infected children in Brazil and Europe (Gilbert *et al.*, 2008). In France, where systematic diagnoses of congenital toxoplasmosis were performed, type II isolates were found in all different aspects of congenital disease, from lethal infection to latent toxoplasmosis, classically depending on the term of pregnancy during which the infection was acquired. On the other hand, the few atypical isolates detected in this country were observed only for severe cases of congenital toxoplasmosis (De-la-Torre *et al.*, 2010). The possibility of reinfection by a different strain is another consequence of this genetic diversity, raising the new concept that immunity against one strain may not be completely protective against another one, as shown for a case of reinfection with an atypical strain leading to severe congenital toxoplasmosis (Elbez-Rubinstein *et al.*, 2009).

#### **CLINICAL FEATURES OF TOXOPLASMOSIS IN HUMANS**

Pathogeny and development of the immune response during the course of infection following the ingestion of cysts or oocysts, the respective excysted forms, bradyzoites or sporozoites, rapidly invade the small intestinal epithelium, where they convert into tachyzoites. The acute early steps of intestinal infection of humans are not well characterized, but the establishment of infection probably relies on the intrinsic properties of the parasites. First, the high motility of tachyzoites and cell interactions between the parasite protein MIC2 and the host intercellular adhesion molecules (ICAM-1) could be used for paracellular crossing. Moreover, the active invasion of the apical side of the epithelial cell could be followed by egress from the basolateral side (transcellular traversal) (Lambert & Barragan, 2010). Whatever the early scenario comprising or not an initial multiplication of tachyzoites in the intestinal epithelium, they further cross the intestinal barrier and invade monocyte cells in contact with the lamina propria, which are key cells for the dissemination of *Toxoplasma* through the blood flow toward all organs, using them as Trojan horses to cross biological barriers (Barragan & Hitziger, 2008; Bierly *et al.*, 2008), as shown with a murine model of infection by intracellular fluorescent parasites (Unno *et al.*, 2008). This peculiar capacity to actively invade all nucleated cells, including

professional phagocytic cells, contributes to the complexity of the host-parasite interactions through the direct modulation of the host immune response.

The cellular and soluble effectors involved in the immune response against *T. gondii* have been extensively studied in the last 2 decades. It was recognized early that a T helper 1 (Th-1) immune response driven by gamma interferon (IFN- $\mu$ ) and interleukin-12 (IL-12)-producing cells is essential for the control of the parasite burden. The fine regulation of immune effectors and their signaling pathways were reviewed recently by Miller *et al.* (Miller *et al.*, 2009). Briefly, following the ingestion and transepithelial transfer of parasites, there is a local release of chemokines by infected cells, leading to the attraction of cells of the innate immunity. Neutrophils are attracted to the infected foci early to phagocytose free parasites and contribute to reducing parasite burdens (Bliss *et al.*, 2001). Other phagocytic cells, such as dendritic cells (DCs) and macrophages, play a pivotal role in the initiation of innate immunity, as they are the major sources of IL-12 as well as IL-18, thus promoting natural killer (NK) and NKT cell activation (Iwasaki *et al.*, 2004), with both cell types producing IFN- $\mu$  in large quantities (French *et al.*, 2006). Moreover, DCs and macrophage cells can present parasite antigens associated with major histocompatibility complex (MHC) class II antigens and costimulatory molecules and further prime T cells (Combe *et al.*, 2006). In addition, DCs and NK cells can also interact directly, with this dialog resulting in the mutual activation and amplification of IL-12 and IFN- $\mu$  synthesis, respectively. Classically, the release of IFN- $\mu$  can trigger macrophage activation to synthesize tumor necrosis factor alpha (TNF- $\alpha$ ), thus being responsible for an amplification loop. The further recognition of parasite antigens by pattern recognition receptors (PRRs) leads to an exacerbation of phagocytic activity with an enhanced production of reactive oxygen species (ROS) and nitric oxide (NO) species and tryptophan starvation through 2-3-indole-amine dioxygenase (IDO) activation (Pfefferkorn, 1984).

However, this potent machinery has two limitations. The first limitation resides in the negative counterpart of a strong Th-1 immune response, which may overwhelm its goal and be responsible for severe inflammation, resulting in intestinal tissue damage or even the death of the susceptible host, as shown with a murine C57BL/6 model (Liesenfeld, 2002). Thus, there is a need for down regulating effectors, a role devoted at least partially to IL-10 and transforming growth factor  $\beta$  (TGF- $\beta$ ), which modulate macrophage activation (Mosser, 2003). Such a deleterious effect of an acute Th-1 immune response is also well known in the setting of primary acquired infection during pregnancy and can result in fetal loss, since IFN- $\mu$  destabilizes the Th-2 microenvironment necessary for maternal-fetal tolerance. Thus, the complexity of the

maternal-fetal interface is magnified by *Toxoplasma* infection, and the role of the placenta in the immunomodulation process is probably essential for the maintenance of gestation after maternal infection (Pfaff *et al.*, 2007; Robert-Gagneux *et al.*, 2011).

On the other hand, despite the powerful host cell effectors described above, recent data provided mechanistic details on how *Toxoplasma* surrounds the host immune system, which makes it a successful parasite persisting lifelong in host tissues. It is now recognized that the parasite rhoptry protein ROP16 can rapidly process into the host cell nucleus, where it interferes with signaling pathways of host immune responses, particularly through the phosphorylation of the STAT3 and STAT6 transcription factors (Saeij *et al.*, 2007), leading to the downregulation of IL-12 production by macrophages and, subsequently, of IFN- $\mu$  (Denkers *et al.*, 2004). Interestingly, this capacity is not shared by all strains but is devoted to type I and III isolates (Saeij *et al.*, 2006). This could partially explain the greater severity usually observed for infections due to strains harboring type I alleles. Moreover, type II strains, which do not exert this capacity to repress the host response, induce a rapid immune response, limiting parasite growth, thereby ensuring the survival of both the host and parasite and resulting in bradyzoite conversion and the encystment of the parasite for persistence. At the same time, it was shown that *Toxoplasma* can also inhibit apoptotic mechanisms of the infected cell by antagonizing caspase 8 (Villena *et al.*, 2010) and interfering with the NF- $\kappa$ B pathway (Laliberte & Carruthers, 2008), thus ensuring both protection against the rapid clearance of intracellular tachyzoites by macrophages and the long-term survival of bradyzoites in the cysts. In the immunocompetent host, the occasional rupture of individual cysts is considered to be responsible for the continuous stimulation of the immune response, which ensures a dynamic control of the cysts.

#### **Toxoplasmosis in Immunocompetent Subjects**

Primary acquired infection is asymptomatic in more than 80% of cases of immunocompetent subjects in European countries or North America (Montoya & Liesenfeld, 2004). In the remaining cases, patients may experience fever or cervical lymphadenopathy, sometimes associated with myalgia, asthenia, or other nonspecific clinical signs. Lymphadenopathy and asthenia may persist for several weeks, mimicking infectious mononucleosis, especially since monocytosis can be observed on blood smears. A study conducted in the United States showed that only 48% of mothers who gave birth to congenitally infected infants could recall clinical signs suitable with toxoplasmosis during their pregnancy (Boyer *et al.*, 2005). More rarely but not exceptionally, toxoplasmic chorioretinitis with visual impairment may reveal primary infection (Montoya & Remington, 1996), although it was previously thought that ocular toxoplasmosis was the result of congenital

infection. Indeed, in a retrospective study by Delair *et al.*, 100 out of 425 (23.5%) consecutive cases of ocular toxoplasmosis were attributed to acquired toxoplasmosis (Delair *et al.*, 2008).

In fact, it is now recognized that the severity of infection may depend on the genotype of the strain. Indeed, as stated above, the severity of infection is low in Western European countries and North America, where type II strains predominate (Howe & Sibley, 1995), but much higher in other parts of the world, such as South America (Demar *et al.*, 2007) or Africa, where other genotypes circulate (Khan *et al.*, 2006; Mercier *et al.*, 2010; Vallochi *et al.*, 2005). In particular, several studies have shown higher incidences and severities of chorioretinitis in Brazil (Gilbert *et al.*, 2008) or Colombia, both during primary infections of immunocompetent subjects and in congenitally infected infants. The strain genotype could also be an explanation for the high proportion of retinochoroiditis (19 of 100 cases with proven acute infection) in an outbreak in Victoria, British Columbia, Canada, where an atypical cougar isolate was suspected to be the cause (Bowie *et al.*, 1997), and for the 100-fold-higher incidence of ocular toxoplasmosis in patients born in Africa than in patients born in Britain (Gilbert *et al.*, 1995). Moreover, in the British Columbia outbreak, 20% of patients had recurrent episodes of retinochoroiditis (Burnett *et al.*, 1998). Such strains with atypical genotypes can also be responsible for severe or lethal infections in immunocompetent subjects, which may take the form of pneumonitis, myocarditis, meningoencephalitis, or polymyositis. Data collected through the Resource Biological Center of the Centre National de Référence de la Toxoplasmose (Limoges, France) showed that among the few severe or lethal infections that occurred from 2007 to 2010 in France, 7 of 10 were related to atypical genotypes acquired in French Guiana (Carme *et al.*, 2002).

#### **Toxoplasmosis in Immunocompromised Patients**

Contrasting with the setting of *Toxoplasma* infection in immunocompetent subjects, toxoplasmosis is always life threatening in immunocompromised patients, whatever the strain, yet the host immune background is of prime importance. Various factors responsible for profoundly impaired cellular immunity can lead to severe toxoplasmosis, among which are HIV infection and immunosuppressive therapies. Patients are more commonly at risk for disease reactivation resulting from cyst rupture than for a newly acquired infection, but the risk may differ among categories of patients. In transplant patients, severe or disseminated toxoplasmosis can result from either a reactivation of latent infection in the recipient or infection from a cyst-containing organ from a seropositive donor given to a seronegative recipient (Botterel *et al.*, 2002; Martina *et al.*, 2011; Rogers *et al.*, 2008), a situation where heart transplants carry the highest risk (Gallino *et al.*, 1996; Sanchez *et al.*, 2011). A reactivation of a chronic

infection may occur in the recipient irrespective of the type of graft, but the risk is closely related to the duration and degree of immunosuppression, with hematopoietic stem cell transplant (HSCT) patients being most at risk (Derouin *et al.*, 1992; Derouin & Pelloux, 2008; Roemer *et al.*, 2001). In HIV-infected patients, the incidence of toxoplasmosis is closely related to CD4+ T cell counts, with an increasing risk when the count falls under 100 cells/ $\mu$ l. Toxoplasmic encephalitis (TE) is the most predominant manifestation of the disease in these patients and can lead to various symptoms, ranging from headache, lethargy, incoordination, or ataxia to hemiparesis, loss of memory, dementia, or focal to major motor seizures, usually associated with fever (Luft & Remington, 1992). The incidence of TE has decreased since the use of highly active antiretroviral therapy (HAART) (Jones *et al.*, 2002), as was shown with a French cohort, where the risk was divided by 4 and fell from 3.9 to 1.0 cases per 100 person-years (Abgrall *et al.*, 2001).

Other organs can be involved, either because they are target organs for encystment and thus are subsequent potential sites for cyst reactivation or because they are secondarily infected following the dissemination of parasites from an initial reactivation site. After the brain, the most frequently involved organs are the lungs, the eyes (Rabaud *et al.*, 1994), and the heart, resulting in myocarditis, but the isolation of *Toxoplasma* from many other sites, such as liver, pancreas (Hofman *et al.*, 1993), bone marrow, bladder (Rabaud *et al.*, 1994), lymph nodes, kidney, spleen, and skin (Arnold *et al.*, 1997), has been documented. Pulmonary or disseminated toxoplasmosis is seen mostly in transplant patients, who develop rapidly progressive infection and a massive dissemination of parasites (Botterel *et al.*, 2002; Derouin *et al.*, 1992; Patrat-Delon *et al.*, 2010). Less frequently, toxoplasmic retinochoroiditis may occur independently of any other signs of evolutive infection and must be distinguished from other infectious etiologies, in particular eye lesions due to cytomegalovirus (CMV), HIV, or syphilis.

### **Congenital Toxoplasmosis**

Classically, congenital infection results from primary acquired maternal infection during gestation. The frequency of vertical transmission and the severity of fetal damage depend on the stage of pregnancy when maternal infection occurs. The placenta plays a main role in the process, as it is both a natural barrier which is supposed to protect the fetus and a target tissue for parasite multiplication (Abbasi *et al.*, 2003). In fact, the placental barrier is more efficient at the beginning of gestation, leading to the passage of parasites in less than 10% of cases during the first trimester, but becomes more permeable throughout pregnancy, allowing parasite transmission in around 30% of cases in the second trimester and 60 to 70% of cases in the third trimester and even more close to the time of delivery

(Dunn *et al.*, 1999). The severity of fetal infection is inversely correlated, since neonates are asymptomatic in more than 80% of cases when infected during the third trimester of gestation (Desmots & Couvreur, 1974). However, when transplacental transmission occurs during the first trimester, the consequences for fetal development are heavy, often leading to severe abnormalities or to abortion. Parasite multiplication induces necrosis foci and strong inflammation, leading to major abnormalities in the brain and eye tissues. It can induce the destruction or profound remodeling of the white substance. Infected necrotized foci may block the aqueduct of Sylvius, resulting in hydrocephalus of lateral ventricles. These foci further calcify and can be detected by transfontanellar echography or cranial X-ray. Major sequelae include mental retardation, seizures, microcephalus, hydrocephalus, deafness, and psychomotor deficiency (Remington *et al.*, 2001). Eye lesions are also more severe in early pregnancy, where microphthalmia, cataract, increased intraocular pressure, strabismus, optic neuritis, and retinal necrosis can be observed (Delair *et al.*, 2011; Roberts *et al.*, 2001), as can uveitis and retinochoroiditis, possibly leading to blindness if retinal lesions affect the macula. During the second trimester, fetal infection can be of variable severity. Echographical ultra sounds may reveal areas of hyperechogenic mesentery, hepatosplenomegaly, or cerebral calcifications. Clinical manifestations at birth may include epilepsy, anemia, thrombocytopenia-induced petechiae, rash, hepatic disorders, pneumonitis, or retinochoroiditis (Remington *et al.*, 2001). In a prospective European study, intracranial lesions detected at birth were associated with serious neurologic disorders in about 30% of cases (Cortina-Borja *et al.*, 2010). Among the data from 272 cases collected in 2007 through the French Surveillance Network (Villena *et al.*, 2010), 11 cases resulted in the termination of pregnancy owing to cerebral lesions or fetal death, and 87% of live-born infants were asymptomatic. The remaining 13% of cases had intracranial calcifications (14 cases), hydrocephalus (3 cases), and/or retinochoroiditis of variable severity (12 cases).

Retinochoroiditis is a common feature that can be observed whatever the time of maternal infection. Its particularity resides in its frequently delayed clinical expression after birth. During a longitudinal U.S. study including 25 infants who were not treated in utero or during their first year of life, Phan *et al.* (Phan *et al.*, 2008) observed that 72% of these infants developed new eye lesions during a mean follow-up time of 5.7 years. Another prospective study of 102 infants who benefited from antenatal and postnatal treatment showed that 78% were asymptomatic during a median follow-up time of 7.8 years (Berrebi *et al.*, 2010). A recent European cohort study showed that the risk of developing eye lesions by 4 years of age was highest for children with serious neurologic sequelae at birth but also significantly increased for those with intracranial

lesions or hepa- tosplenomegaly (Freeman *et al.*, 2008). Conversely, children without retinochoroiditis detected by 4 months were at a low risk of developing eye manifestations by 4 years of age. In any event, the question of long-term pathogenicity may differ according to prevention protocols, and probably according to the strain genotype, as retinal lesions are more extensive in congenitally infected Brazilian infants (Vasconcelos-Santos *et al.*, 2009). Indeed, a comparative prospective cohort study of congenitally infected children in Brazil and Europe showed that, independently of treatment, Brazilian children had a 5-times- higher risk than European children for developing eye lesions, and their lesions were larger, more multiple, more recurrent, and more likely to impair vision (Gilbert *et al.*, 2008).

Although the vast majority of congenital infections results from primary acquired infection during pregnancy, parasite transmission can occur in rare instances in immunocompetent, previously immunized women who are reinfected with *Toxoplasma* during gestation (Elbez-Rubinstein *et al.*, 2009; Gavinet *et al.*, 1997; Hennequin *et al.*, 1997; Kodjikian *et al.*, 2004). A recent case benefited from genotyping, which revealed that reinfection was due to an atypical strain which was responsible for severe congenital toxoplasmosis, raising the temptation to take primary prevention measures even in previously immunized pregnant women, particularly in cases of travel to areas where atypical genotypes circulate (Elbez-Rubinstein *et al.*, 2009). A reactivation of past infection in HIV-infected women can also lead to congenital transmission, as shown by several case reports (Lindsay & Dubey, 2011).

Other exceptional cases of vertical transmission following maternal infection in the 2 months before conception have been described (Desmots *et al.*, 1990; Marty *et al.*, 1991), but in most cases, the immune background of the mother could explain the prolonged dissemination of the parasite and thus further placental colonization and transmission. Another concept which has emerged from the French experience of the systematic screening of pregnancies for >20 years is that parasite transmission can be delayed, since few asymptomatic neonates born to mothers with periconceptional infection were diagnosed with congenital infection after birth despite negative pre- natal screening results (Robert-Gangneux *et al.*, 2009). Indirect arguments also support this hypothesis, since in a study by Romand *et al.* (Romand *et al.*, 2001), the sensitivity of prenatal diagnosis was lower in early pregnancy than in mid-pregnancy, suggesting that vertical transmission may be delayed for some women infected in early pregnancy (Thulliez, 2001). Thus, in rare instances, parasites could persist in the placenta and proceed into the fetal compartment only at the end of gestation, which could explain why neonates may not

have any clinical or radiological signs in utero and at birth.

## DIAGNOSTIC METHODS

The diagnosis of *T. gondii* infection or toxoplasmosis may be established by serologic tests, amplification of specific nucleic acid sequences (i.e., polymerase chain reaction [PCR]), histologic demonstration of the parasite and its antigens (i.e., immunoperoxidase stain), or by isolation of the organism (Remington, *et al.*, 2006).

### Serologic Tests

The use of serologic tests for demonstration of specific anti- body to *T. gondii* is the initial and primary method of diagnosis. Different serologic tests often measure different antibodies that possess unique patterns of rise and fall with time after infection (Montoya & Remington, 1995). A combination of serologic tests is usually required to establish whether an individual has been most likely infected in the distant past or has been recently infected.

A panel of tests (the *Toxoplasma* Serological Profile [TSP]) consisting of the Sabin-Feldman dye test (DT) (Sabin & Feldman, 1948), double sandwich IgM ELISA (Naot & Remington, 1981), IgA ELISA (Stepick-Biek *et al.*, 1990), IgE ELISA (Pinon *et al.*, 1990; Wong *et al.*, 1993), and AC/HS test (Dannemann *et al.*, 1990) has been used successfully by our group to determine if serologic test results are more likely consistent with infection acquired in the recent or more distant past (Liesenfeld *et al.*, 2001; Montoya & Remington, 1996). The AC/HS test is interpreted as previously described (Dannemann *et al.*, 1990) by comparing IgG titers obtained with formalin-fixed tachyzoites (HS antigen) with those obtained with acetone-fixed tachyzoites (AC antigen).

The TSP has been successfully used in the setting of toxoplasmic lymphadenitis (Montoya & Remington, 1995), myocarditis (Montoya *et al.*, 1997), polymyositis (Montoya *et al.*, 1997), and chorioretinitis (Montoya & Remington, 1996) and during pregnancy (Liesenfeld *et al.*, 2001). For sera with positive results in IgG and IgM tests, the discriminatory power of the TSP to differentiate between recently acquired infection and chronic infection is probably superior to any other single serologic test.

IgG antibodies. The most commonly used tests for the measurement of IgG antibody are the DT, the ELISA, the IFA, and the modified direct agglutination test (Thulliez *et al.*, 1986). In these tests, IgG antibodies usually appear within 1– 2 weeks of acquisition of the infection, peak within 1– 2 months, decline at various rates, and usually persist for life. When two different compounds (i.e., acetone and formalin) are used to fix parasites for use in the agglutination test, a “differential” agglutination test (also known as the

“AC/HS test”) results due to the fact that the different antigenic preparations vary in their ability to recognize sera obtained during the acute and chronic stages of the infection. This test has proved useful in helping to differentiate acute from chronic infections (Dannemann *et al.*, 1990) but is best used in combination with a panel of other tests (e.g., the TSP). Recently, a number of tests for avidity of Toxoplasma IgG antibodies have been introduced to help discriminate between recently acquired and distant infection (Hedman *et al.*, 1989; Jenum *et al.*, 1997; Liesenfeld *et al.*, 2001). The functional affinity of specific IgG antibodies is initially low after primary antigenic challenge and increases during subsequent weeks and months by antigen-driven B cell selection. Protein-denaturing reagents including urea are used to dissociate the antibody-antigen complex.

**IgM antibodies.** IgM antibodies may appear earlier and decline more rapidly than IgG antibodies. The most commonly used tests for the measurement of IgM antibody are double-sandwich or capture IgM-ELISA kits (Naot & Remington, 1981), the IFA test, and the immunosorbent agglutination assay (IgM-ISAGA; available from bioMérieux) (Remington *et al.*, 2006). False-positive results due to rheumatoid factor and antinuclear antibodies in some IgM-IFA tests are not detected by the most commonly used commercial double-sandwich or capture IgM-ELISAs (Naot & Remington, 1981). Despite the wide distribution of commercial test kits to measure IgM antibodies, these tests often have low specificity, and the reported results are frequently misinterpreted (Wilson *et al.*, 1997). An IgM test is still used by most laboratories to determine if a patient has been infected recently or in the distant past, and because of the hurdles posed in interpreting a positive IgM test result, confirmatory testing should always be performed.

In patients with recently acquired primary infection, *T. gondii*-specific IgM antibodies are detected initially, and in most cases, these titers become negative within a few months. However, in some patients, positive *T. gondii*-specific IgM titers can still be observed during the chronic phase of infection (Liesenfeld *et al.*, 1997). Some investigators have reported that IgM antibodies can be detected as long as 12 years after the acute infection (Bobic *et al.*, 1991). The persistence of these IgM antibodies does not appear to have any clinical relevance, and these patients should be considered chronically infected. Further complicating the interpretation of a positive IgM test result is the fact that several methods for its detection still may result in a relatively high frequency of false-positive results (Wilson *et al.*, 1997). As is true for IgM antibodies to the parasite, IgA antibodies may persist for many months or more than a year. For this reason, they are of little additional assistance for diagnosis of acute infection in the adult. In contrast, the increased sensitivity of IgA assays over IgM assays for diagnosis

of congenital toxoplasmosis represents an advance in diagnosis of the infection in the fetus and newborn. In a number of newborns with congenital toxoplasmosis and negative IgM antibodies, the serologic diagnosis has been established by the presence of IgA and IgG antibodies (Stepick-Biek *et al.*, 1990). IgE antibodies. IgE antibodies are detectable by ELISA in sera of acutely infected adults, congenitally infected infants, and children with congenital toxoplasmic chorioretinitis (Pinon *et al.*, 1990; Wong *et al.*, 1993).

### PCR

PCR amplification for detection of *T. gondii* DNA in body fluids and tissues has successfully been used to diagnose congenital (Bobic *et al.*, 1991; Grover *et al.*, 1990), ocular (Montoya *et al.*, 1999), and cerebral and disseminated (Brezin *et al.*, 1990; Dupouy-Camet *et al.*, 1993) toxoplasmosis. PCR has revolutionized the diagnosis of intrauterine *T. gondii* infection by enabling an early diagnosis to be made, thereby avoiding the use of more invasive procedures on the fetus. PCR has enabled detection of *T. gondii* DNA in brain tissue (Holliman *et al.*, 1990), cerebrospinal fluid (CSF) (Parmley *et al.*, 1992), vitreous and aqueous fluids (Johnson *et al.*, 1997), bronchoalveolar lavage (BAL) fluid (Roth *et al.*, 1992), and blood (Dupouy-Camet *et al.*, 1993) in patients with AIDS.

### Histologic Diagnosis

Demonstration of tachyzoites in tissue sections or smears of body fluid (e.g., CSF or amniotic or BAL fluids) establishes the diagnosis of the acute infection. It is often difficult to demonstrate tachyzoites in conventionally stained tissue sections. The immunoperoxidase technique, which uses antisera to *T. gondii*, has proven both sensitive and specific: It has been used successfully to demonstrate the presence of the parasite in the central nervous system (CNS) of AIDS patients (Conley *et al.*, 1981). The immunoperoxidase method is applicable to unfixed or formalin-fixed paraffin-embedded tissue sections (Conley *et al.*, 1981). A rapid, technically simple, and under-used method is the detection of *T. gondii* in air-dried, Wright-Giemsa stained slides of centrifuged (e.g., cytocentrifuge) sediment of CSF or of brain aspirate or in impression smears of biopsy tissue. Multiple tissue cysts near an inflammatory necrotic lesion probably establish the diagnosis of acute infection or reactivation of latent infection.

### Isolation of *T. gondii*

Isolation of *T. gondii* from blood or body fluids establishes that the infection is acute. Attempts at isolation of the parasite can be performed by mouse inoculation or inoculation in tissue cell cultures of virtually any human tissue or body fluid.

### Diagnosis of Specific Clinical Entities

The first step in pursuing the diagnosis of *T. gondii* infection or toxoplasmosis is to determine whether the individual has been exposed to the parasite. In essentially all cases, any of the tests for the detection of IgG antibodies reliably establish the presence or absence of the infection. In a small number of patients, IgG antibodies might not be detected within 2–3 weeks after the initial exposure to the parasite; however, this is rare. In addition, rare cases of toxoplasmic chorioretinitis and toxoplasmic encephalitis in immunocompromised patients have been documented in patients with negative *T. gondii*-specific IgG antibodies.

The second step consists of establishing whether the patient has a recently acquired infection or an infection acquired in the more distant past. In general, a true-negative IgM test essentially rules out that the infection has been acquired in recent months. A positive IgM test is more difficult to correctly interpret. One must not assume that a positive IgM test result is diagnostic of recently acquired infection. Confirmatory testing should be done for all cases for whom IgM test results are positive (Liesenfeld *et al.*, 1996). Serologic tests should not be considered useful for measuring response to therapy.

The third step is to establish whether the patient's condition or illness is due to toxoplasmosis (recently acquired infection or recrudescence of latent infection) or is unrelated to the infection.

#### **Toxoplasmosis in the Immunocompetent Patient**

The vast majority of cases of *T. gondii* infection in adults and children are asymptomatic (Remington, 1974). Lymphadenopathy is the most common manifestation in the 10%–20% percent of otherwise immunocompetent individuals whose primary *T. gondii* infection is symptomatic. Less common presentations in these patients include, but are not limited to, chorioretinitis, myocarditis, and/or polymyositis (Montoya & Remington, 2000).

Tests for IgG and IgM antibodies should be used for initial evaluation of these patients. Testing of serial specimens obtained 3–4 weeks apart (in parallel) provides the best discriminatory power if the results in the initial specimen are equivocal. Negative results in both tests virtually rule out the diagnosis of toxoplasmosis. In rare instances early in infection, IgG antibodies may not be detectable, whereas IgM antibodies are present. This means there is need for both tests to be performed. Acute infection is supported by documented seroconversion of IgG and IgM antibodies or a greater than four-fold rise in IgG antibody titer in sera run in parallel. A single high titer of any immunoglobulin is insufficient to make the diagnosis since IgG antibodies may persist at high titers for many years and IgM antibodies may be detectable for 12 months. The TSP, performed on a single serum sample,

is useful in determining the likelihood that the infection is acute. Characteristic histologic criteria and a TSP consistent with recently acquired infection establish the diagnosis of toxoplasmic lymphadenitis in older children and adults (Dorfman & Remington, 1973). Endomyocardial biopsy and biopsy of skeletal muscle has been successfully used to establish *T. gondii* as the etiologic agent of myocarditis and polymyositis in immunocompetent patients. Isolation studies and PCR have rarely proven useful for diagnosis in immunocompetent patients.

#### **Ocular Toxoplasmosis**

Toxoplasmic chorioretinitis may result from congenital or postnatally acquired infection. In both of these situations, lesions may occur during the acute or latent (chronic) stage of the infection (Silveira *et al.*, 1988; Couvreur & Thulliez, 1996). Low titers of IgG antibody are usual in patients with active chorioretinitis due to reactivation of congenital *T. gondii* infection; IgM antibodies usually are not detected. When sera from such patients are examined by use of the DT, titers should be first determined with undiluted serum since in some cases, the conventional initial dilution of 1:16 may be negative. In most cases, toxoplasmic chorioretinitis is diagnosed by ophthalmologic examination, and empiric therapy directed against the organism is often instituted on the basis of clinical findings and serologic test results. In a number of patients, the morphology of the retinal lesion(s) may be non-diagnostic and the response to treatment is suboptimal. In such cases (unclear clinical diagnosis and/or inadequate clinical response), detection of a local and increased *T. gondii* antibody response in ocular fluids (immune load), demonstration of the parasite by isolation or histopathology, or amplification of *T. gondii* DNA (in both aqueous and vitreous fluids) have been used successfully to establish the diagnosis (Holland *et al.*, 1996; Diaz *et al.*, 1997).

#### **Toxoplasmosis in the Immunodeficient Patient**

In contrast to the relatively favorable course of toxoplasmosis in almost all immunocompetent individuals, immunologically impaired patients usually develop a dreadful and often life-threatening disease (Israelski & Remington, 1993). Immunocompromised patients at higher risk for toxoplasmosis include those with hematologic malignancies (particularly patients with lymphoma), bone marrow transplant, solid organ transplant (including heart, lung, liver, or kidney), or AIDS.

Toxoplasmic encephalitis is the most common presentation of toxoplasmosis in immunocompromised patients (Israelski & Remington, 1993) and is the most frequent cause of focal CNS lesions in AIDS patients (Luft & Remington, 1992). It is unclear whether *T. gondii* penetrates the brain more easily than other organs or whether it is more difficult for the brain, as an immunologically privileged site, to eradicate the

organism during the initial acute infection and once residual infection has been established (Montoya & Remington, 1997). A wide range of clinical findings, including altered mental state, seizures, weakness, cranial nerve disturbances, sensory abnormalities, cerebellar signs, meningismus, movement disorders, and neuropsychiatric manifestations are observed in patients with toxoplasmic encephalitis (Liesenfeld & Wong, 1999). Other organs commonly involved in immunocompromised patients with toxoplasmosis are the lungs, eyes, and heart.

In the vast majority of immunocompromised patients, toxoplasmosis results from reactivation of a latent infection. In contrast, in heart transplant patients and in a small number of other immunocompromised patients, the highest risk of developing disease is in the setting of primary infection (i.e., a seronegative recipient who acquires the parasite from a seropositive donor via a graft) (Derouin *et al.*, 1986; Luft *et al.*, 1983). Because reactivation of chronic infection is the most common cause of toxoplasmosis in patients with malignancies or AIDS or in recipients of organ transplants (other than heart transplants), initial assessment of these patients should routinely include an assay for *T. gondii* IgG antibodies. Those with a positive result are at risk of reactivation of the infection; those with a negative result should be instructed on how they can prevent becoming infected. When toxoplasmosis is suspected in immunocompromised patients chronically infected with the parasite (those with documented positive *T. gondii*-specific IgG antibody prior to the onset of immunosuppression) additional serologic testing adds very little (or may be misleading) to the diagnostic evaluation (Luft *et al.*, 1986).

When clinical signs suggest involvement of the CNS and/or spinal cord, tests should include computed tomography or magnetic resonance imaging (MRI) of the brain and/or spinal cord. Neuroimaging studies of the brain should be considered even if the neurologic examination does not reveal focal deficits. Empiric anti-*T. gondii* therapy for patients with multiple ring enhancing brain lesions (usually established by MRI), positive IgG antibody titers against *T. gondii*, and advanced immunodeficiency (i.e., CD4 cell count of, 200 cells/mm<sup>3</sup>) is accepted clinical practice; a clinical and radiologic response to specific anti-*T. gondii* therapy is considered as supportive of the diagnosis of CNS toxoplasmosis. Brain biopsy should be considered in immunocompromised patients with presumed CNS toxoplasmosis if there is a single lesion on MRI, a negative IgG antibody test result, or inadequate clinical response to an optimal treatment regimen or to what the physician considers to be an effective prophylactic regimen against *T. gondii* (e.g., trimethoprim-sulfamethoxazole) (Montoya & Remington, 2000). If *T. gondii* serologic and radiologic studies do not support a recommendation for empiric treatment or are

inconclusive and if brain biopsy is not feasible, a lumbar puncture should be considered if it is safe to perform; PCR can then be performed on the CSF specimen. CSF can also be used for isolation studies, although it is uncommon for *T. gondii* to be isolated from CSF from immunocompromised patients. Of note, PCR examination of CSF can also be used for detection of Epstein-Barr virus, JC virus, or cytomegalovirus DNA in patients in whom primary CNS lymphoma, progressive multifocal leukoencephalopathy, or cytomegalovirus ventriculitis, respectively, have been considered in the differential diagnosis.

### **T. gondii Infection in Pregnancy**

*T. gondii* infection acquired during pregnancy may result in severe damage or death of the fetus and long-term sequelae in offspring. Because congenital toxoplasmosis results almost solely in women who acquire the infection during gestation, it is critical to determine whether infection during pregnancy has occurred. The incidence of congenital toxoplasmosis in the offspring of women infected prior to gestation has been shown to be extremely rare unless a woman is immunocompromised (e.g., receiving corticosteroids or immunosuppressive drugs or positive for human immunodeficiency virus). A negative IgM test result for a pregnant woman in the first 24 weeks of gestation with a low IgG test titer (i.e., DT, 1024) essentially places the acquisition of the infection prior to gestation. In the third trimester, a negative IgM test titer is most likely consistent with a chronic maternal infection but does not exclude the possibility of an acute infection acquired early in pregnancy; this is especially true in those patients who exhibit a rapid decline in their IgM titers during the acute infection. In such cases, the use of other serologic tests (e.g., IgA, IgE, AC/HS, avidity) may be of particular help.

In contrast, a positive IgM test result requires further assessment with confirmatory serologic testing. A false positive IgM test result or its erroneous interpretation can be misleading and result in unnecessary abortions (Liesenfeld *et al.*, 2001). Sixty percent of pregnant women with IgM results determined to be positive by non-reference laboratories were found to be chronically infected when tested at TSL-PAMFRI (Liesenfeld *et al.*, 2001). The potential pitfalls of relying solely on an IgM test as a discriminatory method to allow such distinction and the low reliability of commercial *T. gondii*-specific IgM kits when positive results are obtained have been reported by our group and others (Liesenfeld *et al.*, 1997; Wilson *et al.*, 1997).

### **Congenital Infection in the Fetus and Newborn**

Prenatal diagnosis. Prenatal diagnosis of fetal infection is advised when a diagnosis of acute infection is established or highly suspected in a pregnant woman or an abnormality in the fetus suggests congenital toxoplasmosis. Methods to obtain fetal blood, such as

periumbilical fetal blood sampling, have been largely abandoned because of the risk involved for the fetus and the delay in obtaining definitive results with conventional parasitologic tests (Hohlfeld *et al.*, 1994).

Prenatal diagnosis of congenital toxoplasmosis is currently based on ultrasonography and amniocentesis. PCR on amniotic fluid for detection of *T. gondii*- specific DNA performed from 18 weeks onwards of gestation should be used in all cases of established acute maternal infection or cases with serologic test results highly suggestive of acute acquired infection during pregnancy (Hohlfeld *et al.*, 1994). In a recent report, the overall sensitivity of PCR on amniotic fluid was estimated to be 64%, the negative predictive value was estimated to be 87.8%, and specificity and positive predictive value were estimated to be 100% (Romand *et al.*, 2001); in this study, marked differences in sensitivity were observed depending on the gestational age at the time of the amniocentesis (Romand *et al.*, 2001).

Diagnosis in the newborn. Maternal IgG antibodies present in the newborn may reflect either past or recent infection in the mother. For this reason, tests for detection of IgA and IgM antibodies are commonly employed for diagnosis of infection in the newborn. Serum samples obtained from peripheral blood are preferred. Samples from umbilical cord should not be used as they may be contaminated with maternal blood. Demonstration of IgA antibodies appears to be more sensitive than detection of IgM antibodies for establishing infection in the newborn (Stepick-Biek *et al.*, 1990). *T. gondii*- specific IgA may be present when there is no *T. gondii*- specific IgM, and the converse may also occur. If IgA antibodies are detected in the newborn, the test should be repeated at ~10 days after birth to make certain that what is being measured is not contaminating maternal IgA antibodies. In addition, if the newborn has received a blood transfusion, serologic tests may measure exogenously administered rather than endogenous antibody.

Infants born to mothers chronically infected with *T. gondii* will have maternal *Toxoplasma*-specific IgG antibodies detected in their peripheral blood. In these infants, *Toxoplasma* serologic tests for IgM and IgA antibodies are usually negative, and efforts to detect *T. gondii* in body fluids or tissues (by isolation or PCR) should yield negative results. Follow-up serologic testing should be done on these patients until the IgG antibodies become undetectable. Maternally transferred IgG antibodies should disappear within the first 6–12 months of life. A negative *T. gondii*-specific IgG test result at 1 year of age essentially rules out congenital toxoplasmosis.

Additional diagnostic methods that have been used successfully to diagnose the infection in infants include direct demonstration of the organism by isolation of the parasite (e.g., mouse inoculation or inoculation in tissue cultures of CSF, urine, placental tissue, or peripheral blood) and amplification of *T. gondii*- specific DNA (e.g., PCR in CSF, peripheral blood, or urine) (Remington *et al.*, 2006). Although not clinically available, antigen-specific lymphocyte transformation and lymphocyte typing in response to exposure to *T. gondii* antigens has been used successfully to diagnose the congenital infection in infants >2 months of age (Krahenbuhl *et al.*, 1972 ; Wilson *et al.*, 1980). Specific lymphocyte anergy to the organism may also occur in congenitally infected infants (McLeod *et al.*, 1990).

## CONCLUSION

Advancements in the field of *Toxoplasma* studies have occurred in the past 20 years. There is need of more basic research in the field of molecular and cell biology employing technologies such as genomic and proteomic and if possible to involve imaging techniques. This means another review will be necessary to evaluate these advances. However, in the meantime, epidemiological studies have also gained more importance. The emergence of *Toxoplasma* as a waterborne disease in several countries has stimulated environmental research. An ecological and integrated approach was developed for a better understanding of the complex circulation of *Toxoplasma* between its multiple hosts and the environment and, finally, of the risk factors for human infection. Thanks to the isolation and genotyping of strains from various animal species in different continents which helped in the revelation of diversity of *T. gondii*. There is a need to still evaluate the practical consequences of these epidemiological and genetic advances for diagnosis strategies and for the management of human toxoplasmosis. Available tools for the biological diagnosis of toxoplasmosis allow diagnosis in most cases, but the development of other biomarkers should be helpful for the most difficult cases, for instance, for ocular or cerebral localizations. The diagnosis of *T. gondii* infection or toxoplasmosis can be established by serologic tests, PCR, histologic examination, or isolation of the parasite. *T. gondii* infection can be asymptomatic, and the clinical manifestations of patients with symptomatic toxoplasmosis are protean and nonspecific. The choice of the appropriate diagnostic method(s) and its (their) interpretation may differ for each clinical categories. Therefore in order to optimize the choice and handling of the specimens and their yield, reference laboratories should be contacted prior to diagnostic procedures.

## REFERENCES

1. Abbasi, M., Kowalewska-Grochowska, K., Bahar, M., Kilani, R., Winkler-Lowen, B., & Guilbert, L. (2003). Infection of Placental Trophoblasts by *Toxoplasma gondii*. *The Journal of*



- Infectious Diseases*, 188(4), 608-616. doi:10.1086/377132
2. Abgrall, S., Rabaud, C., & Costagliola, D. (2001). Incidence and Risk Factors for Toxoplasmic Encephalitis in Human Immunodeficiency Virus-Infected Patients before and during the Highly Active Antiretroviral Therapy Era. *Clinical Infectious Diseases*, 33(10), 1747-1755. Doi: 10.1086/322622
3. Abgrall, S., Rabaud, C., & Costagliola, D. (2001). Incidence and Risk Factors for Toxoplasmic Encephalitis in Human Immunodeficiency Virus-Infected Patients before and during the Highly Active Antiretroviral Therapy Era. *Clinical Infectious Diseases*, 33(10), 1747-1755. doi:10.1086/322622
4. Afonso, E., Thulliez, P., & Gilot-Fromont, E. (2009). Local meteorological conditions, dynamics of seroconversion to *Toxoplasma gondii* in cats (*Felis catus*) and oocyst burden in a rural environment. *Epidemiology and Infection*, 138(8), 1105-1113. doi:10.1017/s0950268809991270
5. Afonso, E., Thulliez, P., & Gilot-Fromont, E. (2009). Local meteorological conditions, dynamics of seroconversion to *Toxoplasma gondii* in cats (*Felis catus*) and oocyst burden in a rural environment. *Epidemiology and Infection*, 138(8), 1105-1113. doi:10.1017/s0950268809991270
- 5a. Windal, P. M. (2015). [Http://www.editions-ems.fr/revues/decisions-marketing/articlerevue/1506-la-carte-et-le-territoire-une-nouvelle-lecture-des-frontieres-et-des-mesures-d-importance-et-d-asymetrie-des-attributs-dans-le-modele-tetraclasse.html](http://www.editions-ems.fr/revues/decisions-marketing/articlerevue/1506-la-carte-et-le-territoire-une-nouvelle-lecture-des-frontieres-et-des-mesures-d-importance-et-d-asymetrie-des-attributs-dans-le-modele-tetraclasse.html). *Décisions Marketing*, 79, 113-130. doi:10.7193/dm.079.113.130
6. Henriquez, F. L. (2008). *Toxoplasma*. Molecular and Cellular Biology. (ed. J. W. Ajioka and D. Soldati) pp. 626. Horizon Bioscience, Wymondham, Norfolk, UK, 2007. ISBN 978-1-904933-34-2. £150 (US\$300). *Parasitology*, 135(11), 1353-1353. Doi: 10.1017/s0031182008004861
7. Ajzenberg, D., Bañuls, A., Su, C., Dumètre, A., Demar, M., Carne, B., & Dardé, M. (2004). Genetic diversity, clonality and sexuality in *Toxoplasma gondii*. *International Journal for Parasitology*, 34(10), 1185-1196. doi:10.1016/j.ijpara.2004.06.007
8. Ajzenberg, D., Bañuls, A., Tibayrenc, M., & Dardé, M. L. (2002). Microsatellite analysis of *Toxoplasma gondii* shows considerable polymorphism structured into two main clonal groups. *International Journal for Parasitology*, 32(1), 27-38. Doi: 10.1016/s0020-7519(01)00301-0
9. Ajzenberg, D., Cogné, N., Paris, L., Bessières, M., Thulliez, P., Filisetti, D., Dardé, M. (2002). Genotype of 86 *Toxoplasma gondii* Isolates Associated with Human Congenital Toxoplasmosis, and Correlation with Clinical Findings. *The Journal of Infectious Diseases*, 186(5), 684-689. Doi: 10.1086/342663
10. Ajzenberg, D., Collinet, F., Mercier, A., Vignoles, P., & Dardé, M. (2010). Genotyping of *Toxoplasma gondii* isolates with 15 Microsatellite Markers in a Single Multiplex PCR Assay. *Journal of Clinical Microbiology*, 48(12), 4641-4645. doi:10.1128/jcm.01152-10
11. Ajzenberg, D., Dumetre, A., & Darde, M. (2005). Multiplex PCR for Typing Strains of *Toxoplasma gondii*. *Journal of Clinical Microbiology*, 43(4), 1940-1943. doi:10.1128/jcm.43.4.1940-1943.2005
12. Dardé, M., Ajzenberg, D., & Smith, J. (2007). Population Structure and Epidemiology of *Toxoplasma gondii*. *Toxoplasma Gondii*, 49-80. doi:10.1016/b978-012369542-0/50005-2
13. Albat B, Serre I, Pratlong F, Thevenet A, Baldet P. (1992). Opportunistic toxoplasmosis in a case of heart transplantation. *Agressologie* 33(Spec No 2):103-104. (In French.)
14. Alfonso Y, et al. (2009). Molecular diagnosis of *Toxoplasma gondii* infection in cerebrospinal fluid from AIDS patients. *Cerebrospinal Fluid Res.* 6:2.
15. Andrade GM, et al. (2010). Congenital toxoplasmosis from a chronically infected woman with reactivation of retinochoroiditis during pregnancy. *J. Pediatr. (Rio J.)* 86:85-88.
16. Aramini JJ, et al. (1999). Potential contamination of drinking water with *Toxoplasma gondii* oocysts. *Epidemiol. Infect.* 122:305-315.
17. Arnold SJ, Kinney MC, McCormick MS, Dummer S, Scott MA. (1997). Disseminated toxoplasmosis. Unusual presentations in the immunocompromised host. *Arch. Pathol. Lab. Med.* 121:869-873.
18. Aubert D, et al. (2010). Molecular and biological characteristics of *Toxoplasma gondii* isolates from wildlife in France. *Vet. Parasitol.* 171: 346-349.
19. Baden LR, et al. (2003). Successful toxoplasmosis prophylaxis after orthotopic cardiac transplantation with trimethoprim-sulfamethoxazole. *Transplantation* 75:339-343.
20. Bahia-Oliveira LM, et al. (2003). Highly endemic, waterborne toxoplasmosis in north Rio de Janeiro state, Brazil. *Emerg. Infect. Dis.* 9:55-62.
21. Balasundaram MB, Andavar R, Palaniswamy M, Venkatapathy N. (2010). Outbreak of acquired ocular toxoplasmosis involving 248 patients. *Arch. Ophthalmol.* 128:28-32.
22. Baran DA, et al. (2006). Is toxoplasmosis prophylaxis necessary in cardiac transplantation? Long-term follow-up at two transplant centers. *J. Heart Lung Transplant.* 25:1380-1382.
23. Baril L, et al. (1999). Risk factors for *Toxoplasma* infection in pregnancy: a case-control study in France. *Scand. J. Infect. Dis.* 31:305-309.
24. Barragan A, Hitziger N. (2008). Transepithelial migration by *Toxoplasma*. *Subcell. Biochem.* 47:198-207.

25. Barragan A, Sibley LD. (2002). Transepithelial migration of *Toxoplasma gondii* is linked to parasite motility and virulence. *J. Exp. Med.* 195:1625–1633.
26. Bastien P. (2002). Molecular diagnosis of toxoplasmosis. *Trans. R. Soc. Trop. Med. Hyg.* 96(Suppl 1):S205–S215.
27. Bastien P, Jumas-Bilak E, Varlet-Marie E, Marty P. (2007). Three years of multi-laboratory external quality control for the molecular detection of *Toxoplasma gondii* in amniotic fluid in France. *Clin. Microbiol. Infect.* 13:430–433.
28. Beghetto E, et al. (2003). Use of an immunoglobulin G avidity assay based on recombinant antigens for diagnosis of primary *Toxoplasma gondii* infection during pregnancy. *J. Clin. Microbiol.* 41:5414–5418.
29. Benenson MW, Takafuji ET, Lemon SM, Greenup RL, Sulzer AJ. (1982). Oocyst-transmitted toxoplasmosis associated with ingestion of contaminated water. *N. Engl. J. Med.* 307:666–669.
30. Beraud G, et al. (2009). Cotrimoxazole for treatment of cerebral toxoplasmosis: an observational cohort study during 1994–2006. *Am. J. Trop. Med. Hyg.* 80:583–587.
31. Berger F, Goulet V, Le Strat Y, Desenclos JC. (2009). Toxoplasmosis among pregnant women in France: risk factors and change of prevalence between 1995 and 2003. *Rev. Epidemiol. Sante Publique* 57:241–248.
32. Berrebi A, et al. (2010). Long-term outcome of children with congenital toxoplasmosis. *Am. J. Obstet. Gynecol.* 203:552 e551–556.
33. Bessieres MH, et al. (2009). Diagnosis of congenital toxoplasmosis: pre-natal and neonatal evaluation of methods used in Toulouse University Hospital and incidence of congenital toxoplasmosis. *Mem. Inst. Oswaldo Cruz* 104:389–392.
34. Bessieres MH, et al. (2001). Neonatal screening for congenital toxoplasmosis in a cohort of 165 women infected during pregnancy and influence of in utero treatment on the results of neonatal tests. *Eur. J. Obstet. Gynecol. Reprod. Biol.* 94:37–45.
35. Bierly AL, Shufesky WJ, Sukhumavasi W, Morelli AE, Denkers EY. (2008). Dendritic cells expressing plasmacytoid marker PDCA-1 are Trojan horses during *Toxoplasma gondii* infection. *J. Immunol.* 181:8485–8491.
36. Black MW, Boothroyd JC. (2000). Lytic cycle of *Toxoplasma gondii*. *Microbiol. Mol. Biol. Rev.* 64:607–623.
37. Blanc-Jouvan M, et al. (1996). Chorioretinitis following liver transplantation: detection of *Toxoplasma gondii* in aqueous humor. *Clin. Infect. Dis.* 22:184–185.
38. Bliss SK, Gavrilesco LC, Alcaraz A, Denkers EY. (2001). Neutrophil depletion during *Toxoplasma gondii* infection leads to impaired immunity and lethal systemic pathology. *Infect. Immun.* 69:4898–4905.
39. Botterel F, et al. (2002). Disseminated toxoplasmosis, resulting from infection of allograft, after orthotopic liver transplantation: usefulness of quantitative PCR. *J. Clin. Microbiol.* 40:1648–1650.
40. Bowie WR, et al. (1997). Outbreak of toxoplasmosis associated with municipal drinking water. *Lancet* 350:173–177.
41. Boyer K, et al. (2011). Unrecognized ingestion of *Toxoplasma gondii* oocysts leads to congenital toxoplasmosis and causes epidemics in North America. *Clin. Infect. Dis.* 53:1081–1089.
42. Boyer KM, et al. (2005). Risk factors for *Toxoplasma gondii* infection in mothers of infants with congenital toxoplasmosis: implications for pre-natal management and screening. *Am. J. Obstet. Gynecol.* 192:564–571.
43. Boyle JP, et al. (2006). Just one cross appears capable of dramatically altering the population biology of a eukaryotic pathogen like *Toxoplasma gondii*. *Proc. Natl. Acad. Sci. U. S. A.* 103:10514–10519.
44. Bretagne S, et al. (2000). Prospective study of *Toxoplasma* reactivation by polymerase chain reaction in allogeneic stem-cell transplant recipients. *Transpl. Infect. Dis.* 2:127–132.
45. Brezin AP, et al. (2003). Ophthalmic outcomes after prenatal and post-natal treatment of congenital toxoplasmosis. *Am. J. Ophthalmol.* 135: 779–784.
46. Burg JL, Grover CM, Pouletty P, Boothroyd JC. (1989). Direct and sensitive detection of a pathogenic protozoan, *Toxoplasma gondii*, by polymerase chain reaction. *J. Clin. Microbiol.* 27:1787–1792.
47. Burnett AJ, et al. (1998). Multiple cases of acquired toxoplasmosis retinitis presenting in an outbreak. *Ophthalmology* 105:1032–1037.
48. Campbell AL, et al. (2006). First case of toxoplasmosis following small bowel transplantation and systematic review of tissue-invasive toxoplasmosis following noncardiac solid organ transplantation. *Transplantation* 81:408–417.
49. Carme B, et al. (2002). Severe acquired toxoplasmosis in immunocompetent adult patients in French Guiana. *J. Clin. Microbiol.* 40:4037–4044.
50. Carruthers V, Boothroyd JC. (2007). Pulling together: an integrated model of *Toxoplasma* cell invasion. *Curr. Opin. Microbiol.* 10:83–89.
51. Cavailles P, et al. (2006). The rat *Tox1* locus directs toxoplasmosis outcome and controls parasite proliferation and spreading by macrophage-dependent mechanisms. *Proc. Natl. Acad. Sci. U. S. A.* 103:744–749.
52. Cavattoni I, et al. (2010). Diagnosis of *Toxoplasma gondii* infection after allogeneic stem cell transplant can be difficult and requires intensive scrutiny. *Leuk. Lymphoma* 51:1530–1535.

53. Cazenave J, Cheyrou A, Blouin P, Johnson AM, Begueret J. (1991). Use of polymerase chain reaction to detect *Toxoplasma*. *J. Clin. Pathol.* 44: 1037.
54. Chapey E, Wallon M, Debize G, Rabilloud M, Peyron F. (2010). Diagnosis of congenital toxoplasmosis by using a whole-blood gamma interferon release assay. *J. Clin. Microbiol.* 48:41–45.
55. Chemla C, Villena I, Trenque T, Pinon JM. (2005). Prenatal treatment of congenital toxoplasmosis. *Presse Med.* 34:1719. (In French.)
56. Chiquet C, Fleury J, Blanc-Jouvan M, Wallon M, Boibieux A. (2000). Acquired ocular toxoplasmosis (panuveitis) after liver transplantation. *J. Fr. Ophthalmol.* 23:375–379. (In French.)
57. Cingolani A, et al. 1996. PCR detection of *Toxoplasma gondii* DNA in CSF for the differential diagnosis of AIDS-related focal brain lesions. *J. Med. Microbiol.* 45:472–476.
58. Colombo FA, et al. (2005). Diagnosis of cerebral toxoplasmosis in AIDS patients in Brazil: importance of molecular and immunological methods using peripheral blood samples. *J. Clin. Microbiol.* 43:5044–5047.
59. Combe CL, et al. (2006). Lack of IL-15 results in the suboptimal priming of CD4+ T cell response against an intracellular parasite. *Proc. Natl. Acad. Sci. U. S. A.* 103:6635–6640.
60. Conrad PA, et al. (2005). Transmission of *Toxoplasma*: clues from the study of sea otters as sentinels of *Toxoplasma gondii* flow into the marine environment. *Int. J. Parasitol.* 35:1155–1168.
61. Cook AJ, et al. (2000). Sources of *Toxoplasma* infection in pregnant women: European multicentre case-control study. *BMJ* 321:142–147.
62. Cornu C, et al. (2009). Factors affecting the adherence to an antenatal screening programme: an experience with toxoplasmosis screening in France. *Euro Surveill.* 14:21–25.
63. Correia CC, Melo HR, Costa VM. (2010). Influence of neurotoxoplasmosis characteristics on real-time PCR sensitivity among AIDS patients in Brazil. *Trans. R. Soc. Trop. Med. Hyg.* 104:24–28.
64. Cortina-Borja M, et al. (2010). Prenatal treatment for serious neurological sequelae of congenital toxoplasmosis: an observational prospective cohort study. *PLoS Med.* 7:pii=e1000351.
65. Cristina N, Liaud MF, Santoro F, Oury B, Ambroise-Thomas P. (1991). A family of repeated DNA sequences in *Toxoplasma gondii*: cloning, sequence analysis, and use in strain characterization. *Exp. Parasitol.* 73:73–81.
66. Dabritz HA, et al. (2007). Detection of *Toxoplasma gondii*-like oocysts in cat feces and estimates of the environmental oocyst burden. *J. Am. Vet. Med. Assoc.* 231:1676–1684.
67. Dabritz HA, et al. (2008). Risk factors for *Toxoplasma gondii* infection in wild rodents from central coastal California and a review of *T. gondii* prevalence in rodents. *J. Parasitol.* 94:675–683.
68. Darde ML. (2008). *Toxoplasma gondii*, “new” genotypes and virulence. *Parasite* 15:366–371.
69. Darde ML, Bouteille B, Pestre-Alexandre M. (1992). Isoenzyme analysis of 35 *Toxoplasma gondii* isolates and the biological and epidemiological implications. *J. Parasitol.* 78:786–794.
70. Darde ML, Bouteille B, Pestre-Alexandre M. (1988). Isoenzymic characterization of seven strains of *Toxoplasma gondii* by isoelectrofocusing in polyacrylamide gels. *Am. J. Trop. Med. Hyg.* 39:551–558.
71. Delair E, et al. (2011). Clinical manifestations of ocular toxoplasmosis. *Ocul. Immunol. Inflamm.* 19:91–102.
72. Delair E, et al. (2008). Respective roles of acquired and congenital infections in presumed ocular toxoplasmosis. *Am. J. Ophthalmol.* 146:851–855.
73. De-la-Torre A, Gonzalez G, Diaz-Ramirez J, Gomez-Marin JE. (2007). Screening by ophthalmoscopy for *Toxoplasma* retinochoroiditis in Colombia. *Am. J. Ophthalmol.* 143:354–356.
74. Delhaes L, et al. (2010). Severe congenital toxoplasmosis due to a *Toxoplasma gondii* strain with an atypical genotype: case report and review. *Prenat. Diagn.* 30:902–905.
75. Demar M, et al. (2007). Fatal outbreak of human toxoplasmosis along the Maroni River: epidemiological, clinical, and parasitological aspects. *Clin. Infect. Dis.* 45:e88–e95.
76. De Moura L, et al. (2006). Waterborne toxoplasmosis, Brazil, from field to gene. *Emerg. Infect. Dis.* 12:326–329.
77. Denkers EY, Butcher BA, Del Rio L, Kim L. (2004). Manipulation of mitogen-activated protein kinase/nuclear factor-kappaB-signaling cascades during intracellular *Toxoplasma gondii* infection. *Immunol. Rev.* 201:191–205.
78. Derouin F, et al. (1992). Toxoplasmosis in bone marrow-transplant recipients: report of seven cases and review. *Clin. Infect. Dis.* 15:267–270.
79. Derouin F, et al. (1986). *Toxoplasma* infection after human allogeneic bone marrow transplantation: clinical and serological study of 80 patients. *Bone Marrow Transplant.* 1:67–73.
80. Derouin F, et al. (1996). Predictive value of *Toxoplasma gondii* antibody titres on the occurrence of toxoplasmic encephalitis in HIV-infected patients. *AIDS* 10:1521–1527.
81. Derouin F, Pelloux H. (2008.) Prevention of toxoplasmosis in transplant patients. *Clin. Microbiol. Infect.* 14:1089–1101.
82. De Salvador-Guillouet F, et al. (2006). Severe pneumonia during primary infection with an atypical

- strain of *Toxoplasma gondii* in an immuno-competent young man. *J. Infect.* 53:e47–e50.
83. Desmonts G, Couvreur J. (1974). Congenital toxoplasmosis. A prospective study of 378 pregnancies. *N. Engl. J. Med.* 290:1110–1116.
84. Desmonts G, Couvreur J, Thulliez P. (1990). Congenital toxoplasmosis. 5 cases of mother-to-child transmission of pre-pregnancy infection. *Presse Med.* 19:1445–1449. (In French.)
85. Desmonts G, et al. (1985). Prenatal diagnosis of congenital toxoplasmosis. *Lancet* i:500–504.
86. De Sousa S, et al. (2006). Biologic and molecular characterization of *Toxoplasma gondii* isolates from pigs from Portugal. *Vet. Parasitol.* 135: 133–136.
87. De Thoisy B, Demar M, Aznar C, Carme B. (2003). Ecologic correlates of *Toxoplasma gondii* exposure in free-ranging Neotropical mammals. *J. Wildl. Dis.* 39:456–459.
88. Doesch AO, et al. (2010). Negative pretransplant serostatus for *Toxoplasma gondii* is associated with impaired survival after heart transplantation. *Transpl. Int.* 23:382–389.
89. Dos Santos TR, et al. (2010). Detection of *Toxoplasma gondii* oocysts in environmental samples from public schools. *Vet. Parasitol.* 171:53–57.
90. Dubey JP. (1998). Advances in the life cycle of *Toxoplasma gondii*. *Int. J. Parasitol.* 28:1019–1024.
91. Dubey JP. (1988). Long-term persistence of *Toxoplasma gondii* in tissues of pigs inoculated with *T. gondii* oocysts and effect of freezing on viability of tissue cysts in pork. *Am. J. Vet. Res.* 49:910–913.
92. Dubey JP. (1998). Refinement of pepsin digestion method for isolation of *Toxoplasma gondii* from infected tissues. *Vet. Parasitol.* 74:75–77.
93. Dubey JP. (2010). *Toxoplasmosis of animals and humans*, 2nd ed. CRC Press, Boca Raton, FL.
94. Dubey JP, Ferreira L, Martins J, Jones J. (2011). Sporulation and survival of *Toxoplasma gondii* oocysts in different types of commercial cat litters. *J. Parasitol.* 97:751–754.
95. Dubey JP, Frenkel JK. (1972). Cyst-induced toxoplasmosis in cats. *J. Protozool.* 19:155–177.
96. Dubey JP, et al. (2002). High prevalence of viable *Toxoplasma gondii* infection in market weight pigs from a farm in Massachusetts. *J. Parasitol.* 88:1234–1238.
97. Dubey JP, et al. (2005). Prevalence of viable *Toxoplasma gondii* in beef, chicken, and pork from retail meat stores in the United States: risk assessment to consumers. *J. Parasitol.* 91:1082–1093.
98. Dubey JP, Huong LT, Sundar N, Su C. (2007). Genetic characterization of *Toxoplasma gondii* isolates in dogs from Vietnam suggests their South American origin. *Vet. Parasitol.* 146:347–351.
99. Dubey JP, Jones JL. (2008). *Toxoplasma gondii* infection in humans and animals in the United States. *Int. J. Parasitol.* 38:1257–1278.
100. Dubey JP, Kotula AW, Sharar A, Andrews CD, Lindsay DS. (1990). Effect of high temperature on infectivity of *Toxoplasma gondii* tissue cysts in pork. *J. Parasitol.* 76:201–204.
101. Dubey JP, Lindsay DS, Speer CA. (1998). Structures of *Toxoplasma gondii* tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts. *Clin. Microbiol. Rev.* 11:267–299.
102. Dubey JP, et al. (2006). Characterization of *Toxoplasma gondii* isolates in free-range chickens from Chile, South America. *Vet. Parasitol.* 140:76–82.
103. Dubey JP, et al. (2008). Isolation and genetic characterization of *Toxoplasma gondii* from raccoons (*Procyon lotor*), cats (*Felis domesticus*), striped skunk (*Mephitis mephitis*), black bear (*Ursus americanus*), and cougar (*Puma concolor*) from Canada. *J. Parasitol.* 94:42–45.
104. Dubey JP, et al. (2007). Prevalence of *Toxoplasma gondii* in dogs from Sri Lanka and genetic characterization of the parasite isolates. *Vet. Parasitol.* 146:341–346.
105. Dubey JP, et al. (2011). High prevalence and genotypes of *Toxoplasma gondii* isolated from goats, from a retail meat store, destined for human consumption in the USA. *Int. J. Parasitol.* 41:827–833.
106. Dubey JP, et al. (2008). High prevalence and abundant atypical genotypes of *Toxoplasma gondii* isolated from lambs destined for human consumption in the USA. *Int. J. Parasitol.* 38:999–1006.
107. Dubey JP, Thulliez P. (1993). Persistence of tissue cysts in edible tissues of cattle fed *Toxoplasma gondii* oocysts. *Am. J. Vet. Res.* 54:270–273.
108. Dubremetz JF. (2007). Rhoptries are major players in *Toxoplasma gondii* invasion and host cell interaction. *Cell. Microbiol.* 9:841–848.
109. Dumetre A, Darde ML. (2007). Detection of *Toxoplasma gondii* in water by an immunomagnetic separation method targeting the sporocysts. *Parasitol. Res.* 101:989–996.
110. Dumetre A, Darde ML. (2003). How to detect *Toxoplasma gondii* oocysts in environmental samples? *FEMS Microbiol. Rev.* 27:651–661.
111. Dumetre A, et al. (2008). Effects of ozone and ultraviolet radiation treatments on the infectivity of *Toxoplasma gondii* oocysts. *Vet. Parasitol.* 153:209–213.
112. Duncanson P, Terry RS, Smith JE, Hide G. (2001). High levels of congenital transmission of *Toxoplasma gondii* in a commercial sheep flock. *Int. J. Parasitol.* 31:1699–1703.
113. Dunn D, et al. (1999). Mother-to-child transmission of toxoplasmosis: risk estimates for clinical counselling. *Lancet* 353:1829–1833.
114. Duszynski DW, Lee Couch L. (2000) *Coccidia (Eimeriidae) of Canidae and Felidae*. Upton SJ.

- August, posting date. <http://biology.unm.edu/biology/coccidia/carniv1.html>.
115. Elbez-Rubinstein A, et al. (2009). Congenital toxoplasmosis and reinfection during pregnancy: case report, strain characterization, experimental model of reinfection, and review. *J. Infect. Dis.* 199:280–285.
116. El Hajj H, et al. (2007). ROP18 is a rhoptry kinase controlling the intra-cellular proliferation of *Toxoplasma gondii*. *PLoS Pathog.* 3:e14.
117. Ertug S, Okyay P, Turkmen M, Yuksel H. (2005). Seroprevalence and risk factors for *Toxoplasma* infection among pregnant women in Aydin province, Turkey. *BMC Public Health* 5:66.
118. Eskild A, Magnus P. (2001). Little evidence of effective prenatal treatment against congenital toxoplasmosis—the implications for testing in pregnancy. *Int. J. Epidemiol.* 30:1314–1315.
119. Esmerini PO, Gennari SM, Pena HF. (2010). Analysis of marine bivalve shellfish from the fish market in Santos city, Sao Paulo state, Brazil, for *Toxoplasma gondii*. *Vet. Parasitol.* 170:8–13.
- 119 a. European Food Safety Authority. (2007). Surveillance and monitoring of *Toxoplasma* in humans, food and animals: scientific opinion of the Panel on Biological Hazards. *EFSA J.* 5:83:1–64. <http://www.efsa.europa.eu/fr/efsajournal/pub/583.htm>.
120. Fardeau C, et al. (2002). Diagnosis of toxoplasmic retinochoroiditis with atypical clinical features. *Am. J. Ophthalmol.* 134:196–203.
121. Fekkar A, et al. (2011). Direct genotyping of *Toxoplasma gondii* in ocular fluid samples from 20 patients with ocular toxoplasmosis: predominance of type II in France. *J. Clin. Microbiol.* 49:1513–1517.
122. Fekkar A, et al. (2008). Comparison of immunoblotting, calculation of the Goldmann-Witmer coefficient and real-time PCR using aqueous humor samples for diagnosis of ocular toxoplasmosis. *J. Clin. Microbiol.* 46: 1965–1967.
123. Ferguson DJ. (2002). *Toxoplasma gondii* and sex: essential or optional extra? *Trends Parasitol.* 18:355–359.
124. Ferguson DJ. (2004). Use of molecular and ultrastructural markers to evaluate stage conversion of *Toxoplasma gondii* in both the intermediate and definitive host. *Int. J. Parasitol.* 34:347–360.
125. Fernandez-Sabe N, et al. (2011). Risk factors, clinical features, and outcomes of toxoplasmosis in solid-organ transplant recipients: a matched case-control study. *Clin. Infect. Dis.* 54:355–361.
126. Foudrinier F, et al. (2003). Clinical value of specific immunoglobulin E detection by enzyme-linked immunosorbent assay in cases of acquired and congenital toxoplasmosis. *J. Clin. Microbiol.* 41:1681–1686.
127. Foulon W, et al. (1999). Prenatal diagnosis of congenital toxoplasmosis: a multicenter evaluation of different diagnostic parameters. *Am. J. Obstet. Gynecol.* 181:843–847.
128. Foulon W, et al. (1999). Treatment of toxoplasmosis during pregnancy: a multicenter study of impact on fetal transmission and children's sequelae at age 1 year. *Am. J. Obstet. Gynecol.* 180:410–415.
129. Franck J, Garin YJ, Dumon H. (2008). LDBio-Toxo II immunoglobulin G Western blot confirmatory test for anti-*Toxoplasma* antibody detection. *J. Clin. Microbiol.* 46:2334–2338.
130. Franzen C, et al. (1997). Limited value of PCR for detection of *Toxoplasma gondii* in blood from human immunodeficiency virus-infected patients. *J. Clin. Microbiol.* 35:2639–2641.
131. Freeman K, et al. (2008). Predictors of retinochoroiditis in children with congenital toxoplasmosis: European, prospective cohort study. *Pediatrics* 121:e1215–e1222.
132. French AR, Holroyd EB, Yang L, Kim S, Yokoyama WM. (2006). IL-18 acts synergistically with IL-15 in stimulating natural killer cell proliferation. *Cytokine* 35:229–234.
133. Frenkel JK, Dubey JP, Miller NL. (1970). *Toxoplasma gondii* in cats: fecal stages identified as coccidian oocysts. *Science* 167:893–896.
134. Fricker-Hidalgo H, et al. (2007). Value of *Toxoplasma gondii* detection in one hundred thirty-three placentas for the diagnosis of congenital toxoplasmosis. *Pediatr. Infect. Dis. J.* 26:845–846.
135. Fricker-Hidalgo H, et al. (2005). Disseminated toxoplasmosis with pulmonary involvement after heart transplantation. *Transpl. Infect. Dis.* 7:38–40.
136. Fricker-Hidalgo H, et al. (2009). Diagnosis of toxoplasmosis after allogeneic stem cell transplantation: results of DNA detection and serological techniques. *Clin. Infect. Dis.* 48:e9–e15.
137. Fricker-Hidalgo H, et al. (1998). Detection of *Toxoplasma gondii* in 94 placentae from infected women by polymerase chain reaction, in vivo, and in vitro cultures. *Placenta* 19:545–549.
138. Fricker-Hidalgo H, et al. (2006). New Vidas assay for *Toxoplasma*-specific IgG avidity: evaluation on 603 sera. *Diagn. Microbiol. Infect. Dis.* 56: 167–172.
139. Gallino A, et al. (1996). Toxoplasmosis in heart transplant recipients. *Eur. J. Clin. Microbiol. Infect. Dis.* 15:389–393.
140. Garbino J, et al. (2005). Infection and rejection in liver transplant patients: a 10-year Swiss single-centre experience. *Swiss Med. Wkly.* 135:587–593.
141. Garin JP, Pellerat J, Maillard, Woehrlé-Heze R. (1968). Theoretical bases of the prevention by spiramycin of congenital toxoplasmosis in pregnant women. *Presse Med.* 76:2266. (In French.)
142. Garweg JG, Garweg SD, Flueckiger F, Jacquier P, Boehnke M. (2004). Aqueous humor and serum immunoblotting for immunoglobulin types G, A, M,

- and E in cases of human ocular toxoplasmosis. *J. Clin. Microbiol.* 42:4593–4598.
143. Garweg JG, Jacquier P, Boehnke M. (2000). Early aqueous humor analysis in patients with human ocular toxoplasmosis. *J. Clin. Microbiol.* 38:996 – 1001.
144. Gavinet MF, et al. (1997). Congenital toxoplasmosis due to maternal reinfection during pregnancy. *J. Clin. Microbiol.* 35:1276–1277.
145. Gilbert R, et al. (2003). Effect of timing and type of treatment on the risk of mother to child transmission of *Toxoplasma gondii*. *BJOG* 110:112–120.
146. Gilbert RE, et al. (2008). Ocular sequelae of congenital toxoplasmosis in Brazil compared with Europe. *PLoS Negl. Trop. Dis.* 2:e277.
147. Gilbert RE, et al. (2001). Effect of prenatal treatment on mother to child transmission of *Toxoplasma gondii*: retrospective cohort study of 554 mother-child pairs in Lyon, France. *Int. J. Epidemiol.* 30:1303–1308.
148. Gilbert RE, Stanford MR, Jackson H, Holliman RE, Sanders MD. (1995). Incidence of acute symptomatic *Toxoplasma retinochoroiditis* in south London according to country of birth. *BMJ* 310:1037–1040.
149. Gilbert RE, et al. (2007). Screening for congenital toxoplasmosis: accuracy of immunoglobulin M and immunoglobulin A tests after birth. *J. Med. Screen.* 14:8–13.
150. Giraldo M, et al. (2002). Immunoglobulin M (IgM)-glycoinositol-phospholipid enzyme-linked immunosorbent assay: an immunoenzymatic assay for discrimination between patients with acute toxoplasmosis and those with persistent parasite-specific IgM antibodies. *J. Clin. Microbiol.* 40:1400–1405.
151. Gollub EL, Leroy V, Gilbert R, Chene G, Wallon M. (2008). Effectiveness of health education on *Toxoplasma*-related knowledge, behaviour, and risk of seroconversion in pregnancy. *Eur. J. Obstet. Gynecol. Reprod. Biol.* 136:137–145.
152. Gomez-Marin JE, et al. (2011). First Colombian multicentric newborn screening for congenital toxoplasmosis. *PLoS Negl. Trop. Dis.* 5:e1195.
153. Gordon SM, et al. (1993). Diagnosis of pulmonary toxoplasmosis by bronchoalveolar lavage in cardiac transplant recipients. *Diagn. Cytopathol.* 9:650–654.
154. Gourishankar S, et al. (2008). The use of donor and recipient screening for *Toxoplasma* in the era of universal trimethoprim sulfamethoxazole prophylaxis. *Transplantation* 85:980–985.
155. Gras L, Gilbert RE, Wallon M, Peyron F, Cortina-Borja M. (2004). Duration of the IgM response in women acquiring *Toxoplasma gondii* during pregnancy: implications for clinical practice and cross-sectional incidence studies. *Epidemiol. Infect.* 132:541–548.
156. Gras L, et al. (2005). Association between prenatal treatment and clinical manifestations of congenital toxoplasmosis in infancy: a cohort study in 13 European centres. *Acta Paediatr.* 94:1721–1731.
157. Gratzl R, et al. (2002). Treatment of toxoplasmosis in pregnancy: concentrations of spiramycin and neospiramycin in maternal serum and amniotic fluid. *Eur. J. Clin. Microbiol. Infect. Dis.* 21:12–16.
158. Grigg ME, Suzuki Y. (2003). Sexual recombination and clonal evolution of virulence in *Toxoplasma*. *Microbes Infect.* 5:685–690.
159. Guerina NG, et al. (1994). Neonatal serologic screening and early treatment for congenital *Toxoplasma gondii* infection. *N. Engl. J. Med.* 330:1858–1863.
160. Guy EC, Joynson DH. (1995). Potential of the polymerase chain reaction in the diagnosis of active *Toxoplasma* infection by detection of parasite in blood. *J. Infect. Dis.* 172:319–322.
161. Hakim M, Esmore D, Wallwork J, English TA, Wreghitt T. (1986). Toxoplasmosis in cardiac transplantation. *Br. Med. J. (Clin. Res. Ed.)* 292:1108.
162. Halos L, et al. (2010). An innovative survey underlining the significant level of contamination by *Toxoplasma gondii* of ovine meat consumed in France. *Int. J. Parasitol.* 40:193–200.
163. Havelaar AH, Kemmeren JM, Kortbeek LM. (2007). Disease burden of congenital toxoplasmosis. *Clin. Infect. Dis.* 44:1467–1474.
164. Hennequin C, et al. (1997). Congenital toxoplasmosis acquired from an immune woman. *Pediatr. Infect. Dis. J.* 16:75–77.
165. Hermanns B, et al. (2001). Fulminant toxoplasmosis in a heart transplant recipient. *Pathol. Res. Pract.* 197:211–215.
166. Herwaldt BL. (2001). Laboratory-acquired parasitic infections from accidental exposures. *Clin. Microbiol. Rev.* 14:659–688.
167. Heukelbach J, et al. (2007). Waterborne toxoplasmosis, northeastern Brazil. *Emerg. Infect. Dis.* 13:287–289.
168. Hill D, et al. (2011). Identification of a sporozoite-specific antigen from *Toxoplasma gondii*. *J. Parasitol.* 97:328–337.
169. Hill DE, et al. (2006). Effects of time and temperature on the viability of *Toxoplasma gondii* tissue cysts in enhanced pork loin. *J. Food Prot.* 69:1961–1965.
170. Hofhuis A, et al. (2011). Decreased prevalence and age-specific risk factors for *Toxoplasma gondii* IgG antibodies in The Netherlands between 1995/1996 and 2006/2007. *Epidemiol. Infect.* 139:530–538.
171. Hofman P, et al. (1993). Extracerebral toxoplasmosis in the acquired immunodeficiency syndrome (AIDS). *Pathol. Res. Pract.* 189:894–901.
172. Holliman RE, Johnson J, Burke M, Adams S, Pepper JR. (1990). False-negative dye-test findings in a case of fatal toxoplasmosis associated with cardiac transplantation. *J. Infect.* 21:185–189.

173. Homan WL, Vercammen M, De Braekeleer J, Verschueren H. (2000). Identification of a 200- to 300-fold repetitive 529 bp DNA fragment in *Toxoplasma gondii*, and its use for diagnostic and quantitative PCR. *Int.J. Parasitol.* 30:69–75.
174. Hotez PJ. (2008). Neglected infections of poverty in the United States of America. *PLoS Negl. Trop. Dis.* 2:e256.
175. Howe DK, Sibley LD. (1995). *Toxoplasma gondii* comprises three clonal lineages: correlation of parasite genotype with human disease. *J. Infect. Dis.* 172:1561–1566.
176. Hutchison WM, Dunachie JF, Siim JC, Work K. (1969). Life cycle of *Toxoplasma gondii*. *Br. Med. J.* iv: 806.
177. Iwasaki A, Medzhitov R. (2004). Toll-like receptor control of the adaptive immune responses. *Nat. Immunol.* 5:987–995.
178. Jokelainen P, Isomursu M, Nareaho A, Oksanen A. (2011). Natural *Toxoplasma gondii* infections in European brown hares and mountain hares in Finland: proportional mortality rate, antibody prevalence, and genetic characterization. *J. Wildl. Dis.* 47:154–163.
179. Jones JL, et al. (2009). Risk factors for *Toxoplasma gondii* infection in the United States. *Clin. Infect. Dis.* 49:878–884.
180. Jones JL, Dubey JP. (2010). Waterborne toxoplasmosis recent developments. *Exp. Parasitol.* 124:10–25.
181. Jones JL, Kruszon-Moran D, Sanders-Lewis K, Wilson M. (2007). *Toxoplasma gondii* infection in the United States, 1999-2004, decline from the prior decade. *Am. J. Trop. Med. Hyg.* 77:405–410.
182. Jones JL, Kruszon-Moran D, Won K, Wilson M, Schantz PM. (2008). *Toxoplasma gondii* and *Toxocara* spp. coinfection. *Am. J. Trop. Med. Hyg.* 78:35–39.
183. Jones JL, Sehgal M, Maguire JH. (2002). Toxoplasmosis-associated deaths among human immunodeficiency virus-infected persons in the United States, 1992-1998. *Clin. Infect. Dis.* 34:1161.
184. Kang YA, et al. (2007). Usefulness of whole-blood interferon-gamma assay and interferon-gamma enzyme-linked immunospot assay in the diagnosis of active pulmonary tuberculosis. *Chest* 132:959–965.
185. Kapperud G, et al. (1996). Risk factors for *Toxoplasma gondii* infection in pregnancy. Results of a prospective case-control study in Norway. *Am. J. Epidemiol.* 144:405–412.
186. Khan A, et al. (2011). Genetic analyses of atypical *Toxoplasma gondii* strains reveal a fourth clonal lineage in North America. *Int. J. Parasitol.* 41:645–655.
187. Khan A, et al. (2007). Recent transcontinental sweep of *Toxoplasma gondii* driven by a single monomorphic chromosome. *Proc. Natl. Acad. Sci. U. S. A.* 104:14872–14877.
188. Khan A, et al. (2006). Genetic divergence of *Toxoplasma gondii* strains associated with ocular toxoplasmosis, Brazil. *Emerg. Infect. Dis.* 12:942–949.
189. Khoshnood B, De Vigan C, Goffinet F, Leroy V. (2007). Prenatal screening and diagnosis of congenital toxoplasmosis: a review of safety issues and psychological consequences for women who undergo screening. *Prenat. Diagn.* 27:395–403.
190. Kieffer F, et al. (2008). Risk factors for retinochoroiditis during the first 2 years of life in infants with treated congenital toxoplasmosis. *Pediatr. Infect. Dis. J.* 27:27–32.
191. Kijlstra A, Jongert E. (2009). *Toxoplasma*-safe meat: close to reality? *Trends Parasitol.* 25:18–22.
192. Kniel KE, et al. (2002). Examination of attachment and survival of *Toxoplasma gondii* oocysts on raspberries and blueberries. *J. Parasitol.* 88: 790–793.
193. Kodjikian L, et al. (2004). Vertical transmission of toxoplasmosis from a chronically infected immunocompetent woman. *Pediatr. Infect. Dis. J.* 23:272–274.
194. Kotresha D, Noordn R. (2010). Recombinant proteins in the diagnosis of toxoplasmosis. *APMIS* 118:529–542.
195. Labalette P, Delhaes L, Margaron F, Fortier B, Rouland JF. (2002). Ocular toxoplasmosis after the fifth decade. *Am. J. Ophthalmol.* 133: 506–515.
196. Lachaud L, et al. (2009). Value of 2 IgG avidity commercial tests used alone or in association to date toxoplasmosis contamination. *Diagn. Microbiol. Infect. Dis.* 64:267–274.
197. Laliberte J, Carruthers VB. (2008). Host cell manipulation by the human pathogen *Toxoplasma gondii*. *Cell. Mol. Life Sci.* 65:1900–1915.
198. Lambert H, Barragan A. (2010). Modelling parasite dissemination: host cell subversion and immune evasion by *Toxoplasma gondii*. *Cell. Microbiol.* 12:292–300.
199. Lamoril J, et al. (1996). Detection by PCR of *Toxoplasma gondii* in blood in the diagnosis of cerebral toxoplasmosis in patients with AIDS. *J. Clin. Pathol.* 49:89–92.
200. Lappalainen M, et al. (1993). Toxoplasmosis acquired during pregnancy: improved serodiagnosis based on avidity of IgG. *J. Infect. Dis.* 167:691–697.
201. Laurans C, et al. (2002). Necessity of postpartum serologic screening for congenital toxoplasmosis in women who are seronegative at the end of pregnancy. *Presse Med.* 31:1266–1267. (In French.)
202. Lefevre-Pettazzoni M, et al. (2007). Impact of spiramycin treatment and gestational age on maturation of *Toxoplasma gondii* immunoglobulin G avidity in pregnant women. *Clin. Vaccine Immunol.* 14:239–243.
203. Lehmann T, et al. (2004). Variation in the structure of *Toxoplasma gondii* and the roles of selfing, drift, and epistatic selection in maintaining linkage disequilibria. *Infect. Genet. Evol.* 4:107–114.

204. Liesenfeld O. (2002). Oral infection of C57BL/6 mice with *Toxoplasma gondii*: a new model of inflammatory bowel disease? *J. Infect. Dis.* 185(Suppl 1):S96–S101.
205. Liesenfeld O, Montoya JG, Kinney S, Press C, Remington JS. (2001). Effect of testing for IgG avidity in the diagnosis of *Toxoplasma gondii* infection in pregnant women: experience in a US reference laboratory. *J. Infect. Dis.* 183:1248–1253.
206. Lindsay DS, Collins MV, Holliman D, Flick GJ, Dubey JP. (2006). Effects of high-pressure processing on *Toxoplasma gondii* tissue cysts in ground pork. *J. Parasitol.* 92:195–196.
207. Lindsay DS, Dubey JP. (2009). Long-term survival of *Toxoplasma gondii* sporulated oocysts in seawater. *J. Parasitol.* 95:1019–1020.
208. Lindsay DS, Dubey JP. (2011). *Toxoplasma gondii*: the changing paradigm of congenital toxoplasmosis. *Parasitology* 138:1829–1831.
209. Lindsay DS, Dubey JP. (2007). Toxoplasmosis in wild and domestic animals, p 133–152. In Weiss LM, Kim K (ed), *Toxoplasma gondii: the model apicomplexan. Perspectives and methods.* Academic Press, London, United Kingdom.
210. Liu Q, et al. (2009). *Toxoplasma gondii* infection in pregnant women in China. *Trans. R. Soc. Trop. Med. Hyg.* 103:162–166.
211. Luft BJ, Naot Y, Araujo FG, Stinson EB, Remington JS. (1983). Primary and reactivated *Toxoplasma* infection in patients with cardiac transplants. Clinical spectrum and problems in diagnosis in a defined population. *Ann. Intern. Med.* 99:27–31.
212. Luft BJ, Remington JS. (1992). Toxoplasmic encephalitis in AIDS. *Clin. Infect. Dis.* 15:211–222.
213. Mai K, et al. (2009). Oocyst wall formation and composition in coccidian parasites. *Mem. Inst. Oswaldo Cruz* 104:281–289.
214. Martina MN, et al. (2011). *Toxoplasma gondii* primary infection in renal transplant recipients. Two case reports and literature review. *Transpl. Int.* 24:e6–e12.
215. Martino R, et al. (2005). Early detection of *Toxoplasma* infection by molecular monitoring of *Toxoplasma gondii* in peripheral blood samples after allogeneic stem cell transplantation. *Clin. Infect. Dis.* 40:67–78.
216. Marty P, Le Fichoux Y, Deville A, Forest H. (1991). Congenital toxoplasmosis and preconceptional maternal ganglionic toxoplasmosis. *Presse Med.* 20:387. (In French.)
217. Mason JC, et al. (1987). Toxoplasmosis in two renal transplant recipients from a single donor. *Transplantation* 44:588–591.
218. Maubon D, Ajzenberg D, Brenier-Pinchart MP, Darde ML, Pelloux H. (2008). What are the respective host and parasite contributions to toxoplasmosis? *Trends Parasitol.* 24:299–303.
219. Mayes JT, O'Connor BJ, Avery R, Castellani W, Carey W. (1995). Transmission of *Toxoplasma gondii* infection by liver transplantation. *Clin. Infect. Dis.* 21:511–515.
220. McAuley J, et al. (1994). Early and longitudinal evaluations of treated infants and children and untreated historical patients with congenital toxoplasmosis: the Chicago Collaborative Treatment Trial. *Clin. Infect. Dis.* 18:38–72.
221. McLeod R, et al. (2006). Outcome of treatment for congenital toxoplasmosis, 1981–2004: the National Collaborative Chicago-Based, Congenital Toxoplasmosis Study. *Clin. Infect. Dis.* 42:1383–1394.
222. Mercier A, et al. (2011). Human impact on genetic diversity of *Toxoplasma gondii*: example of the anthropized environment from French Guiana. *Infect. Genet. Evol.* 11:1378–1387.
223. Mercier A, et al. (2010). Additional haplogroups of *Toxoplasma gondii* out of Africa: population structure and mouse-virulence of strains from Gabon. *PLoS Negl. Trop. Dis.* 4:e876.
224. Mercier C, Adjogble KD, Daubener W, Delaunay MF. (2005). Dense granules: are they key organelles to help understand the parasitophorous vacuole of all apicomplexa parasites? *Int. J. Parasitol.* 35:829–849.
225. Meroni V, et al. (2009). Spiramycin treatment of *Toxoplasma gondii* infection in pregnant women impairs the production and the avidity maturation of *T. gondii*-specific immunoglobulin G antibodies. *Clin. Vaccine Immunol.* 16:1517–1520.
226. Michaels MG, Wald ER, Fricker FJ, del Nido PJ, Armitage J. (1992). Toxoplasmosis in pediatric recipients of heart transplants. *Clin. Infect. Dis.* 14:847–851.
227. Miller CM, Boulter NR, Ikin RJ, Smith NC. (2009). The immunobiology of the innate response to *Toxoplasma gondii*. *Int. J. Parasitol.* 39:23–39.
228. Miller MA, et al. (2008). Type X *Toxoplasma gondii* in a wild mussel and terrestrial carnivores from coastal California: new linkages between terrestrial mammals, runoff and toxoplasmosis of sea otters. *Int. J. Parasitol.* 38:1319–1328.
229. Montoya JG, et al. (2001). Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center. *Clin. Infect. Dis.* 33:629–640.
230. Montoya JG, Liesenfeld O. (2004). Toxoplasmosis. *Lancet* 363:1965–1976.
231. Montoya JG, Parmley S, Liesenfeld O, Jaffe GJ, Remington JS. (1999). Use of the polymerase chain reaction for diagnosis of ocular toxoplasmosis. *Ophthalmology* 106:1554–1563.
232. Montoya JG, Remington JS. (1996). Toxoplasmic chorioretinitis in the setting of acute acquired toxoplasmosis. *Clin. Infect. Dis.* 23:277–282.
233. Mosser DM. (2003). The many faces of macrophage activation. *J. Leukoc. Biol.* 73:209–212.



234. Munoz P, et al. (2003). Trimethoprim-sulfamethoxazole as toxoplasmosis prophylaxis for heart transplant recipients. *Clin. Infect. Dis.* 36:932–933.
235. Naessens A, et al. (1999). Diagnosis of congenital toxoplasmosis in the neonatal period: a multicenter evaluation. *J. Pediatr.* 135:714–719.
236. Nagington J, Martin AL. (1983). Toxoplasmosis and heart transplant. *Lancet* ii: 679.
237. Nascimento FS, Suzuki LA, Rossi CL. (2008). Assessment of the value of detecting specific IgA antibodies for the diagnosis of a recently acquired primary Toxoplasma infection. *Prenat. Diagn.* 28:749–752.
238. Neto EC, et al. (2000). High prevalence of congenital toxoplasmosis in Brazil estimated in a 3-year prospective neonatal screening study. *Int. J. Epidemiol.* 29:941–947.
239. Nicolle C, Manceaux L. (1908). Sur une infection à corps de Leishman (ou organismes voisins) du gondi. *C. R. Hebd. Seances Acad. Sci.* 147:763–766.
240. Nogui FL, Mattas S, Turcato Júnior G, Lewi DS. (2009). Neurotoxoplasmosis diagnosis for HIV-1 patients by real-time PCR of cerebrospinal fluid. *Braz. J. Infect. Dis.* 13:18–23.
241. Novati R, et al. (1994). Polymerase chain reaction for Toxoplasma gondii DNA in the cerebrospinal fluid of AIDS patients with focal brain lesions. *AIDS* 8:1691–1694.
242. Opsteegh M, et al. (2010). Direct detection and genotyping of Toxoplasma gondii in meat samples using magnetic capture and PCR. *Int. J. Food Microbiol.* 139:193–201.
243. Opsteegh M, et al. (2011). Low predictive value of seroprevalence of Toxoplasma gondii in cattle for detection of parasite DNA. *Int. J. Parasitol.* 41:343–354.
244. Orr KE, et al. (1994). Outcome of Toxoplasma gondii mismatches in heart transplant recipients over a period of 8 years. *J. Infect.* 29:249–253.
245. Palanisamy M, Madhavan B, Balasundaram MB, Andavar R, Venkathathy N. (2006). Outbreak of ocular toxoplasmosis in Coimbatore, India. *Indian J. Ophthalmol.* 54:129–131.
246. Pappas G, Roussos N, Falagas ME. (2009). Toxoplasmosis snapshots: global status of Toxoplasma gondii seroprevalence and implications for pregnancy and congenital toxoplasmosis. *Int. J. Parasitol.* 39:1385–1394.
247. Parnley SF, Goebel FD, Remington JS. (1992). Detection of Toxoplasma gondii in cerebrospinal fluid from AIDS patients by polymerase chain reaction. *J. Clin. Microbiol.* 30:3000–3002.
248. Patrat-Delon S, et al. (2010). Correlation of parasite load determined by quantitative PCR to clinical outcome in a heart transplant patient with disseminated toxoplasmosis. *J. Clin. Microbiol.* 48:2541–2545.
249. Paugam A, et al. (1995). Detection of Toxoplasma gondii parasitemia by polymerase chain reaction in perorally infected mice. *Parasite* 2:181–184.
250. Pelloux H, et al. (1998). A second European collaborative study on polymerase chain reaction for Toxoplasma gondii, involving 15 teams. *FEMS Microbiol. Lett.* 165:231–237.
251. Pena HF, Gennari SM, Dubey JP, Su C. (2008). Population structure and mouse-virulence of Toxoplasma gondii in Brazil. *Int. J. Parasitol.* 38: 561–569.
252. Pena HF, et al. (2011). Isolation and genetic characterisation of Toxoplasma gondii from a red-handed howler monkey (Alouatta belzebul), a jaguarundi (Puma yagouaroundi), and a black-eared opossum (Didelphis aurita) from Brazil. *Vet. Parasitol.* 175:377–381.
253. Petersen E, et al. (2005). European multicenter study of the LIAISON automated diagnostic system for determination of Toxoplasma gondii-specific immunoglobulin G (IgG) and IgM and the IgG avidity index. *J. Clin. Microbiol.* 43:1570–1574.
254. Pfaff AW, et al. (2007). Cellular and molecular physiopathology of congenital toxoplasmosis: the dual role of IFN-gamma. *Parasitology* 134: 1895–1902.
255. Pfefferkorn ER. (1984). Interferon gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan. *Proc. Natl. Acad. Sci. U. S. A.* 81:908–912.
256. Phan L, et al. (2008). Longitudinal study of new eye lesions in children with toxoplasmosis who were not treated during the first year of life. *Am. J. Ophthalmol.* 146:375–384.
257. Pietkiewicz H, et al. (2007). Usefulness of Toxoplasma gondii recombinant antigens (GRA1, GRA7 and SAG1) in an immunoglobulin G avidity test for the serodiagnosis of toxoplasmosis. *Parasitol. Res.* 100:333–337.
258. Pinon JM, et al. (1996). Early neonatal diagnosis of congenital toxoplasmosis: value of comparative enzyme-linked immunofiltration assay immunological profiles and anti-Toxoplasma gondii immunoglobulin M (IgM) or IgA immunocapture and implications for postnatal therapeutic strategies. *J. Clin. Microbiol.* 34:579–583.
259. Pinon JM, et al. (2001). Strategy for diagnosis of congenital toxoplasmosis: evaluation of methods comparing mothers and newborns and standard methods for postnatal detection of immunoglobulin G, M, and A antibodies. *J. Clin. Microbiol.* 39:2267–2271.
260. Podzamczar D, et al. (2000). Thrice-weekly sulfadiazine-pyrimethamine for maintenance therapy of toxoplasmic encephalitis in HIV-infected patients. *Eur. J. Clin. Microbiol. Infect. Dis.* 19:89–95.
261. Pomares C, et al. (2011). Toxoplasmosis and horse meat, France. *Emerg. Infect. Dis.* 17:1327–1328.

262. Prestrud KW, et al. (2008). Direct high-resolution genotyping of *Toxoplasma gondii* in arctic foxes (*Vulpes lagopus*) in the remote arctic Svalbard archipelago reveals widespread clonal type II lineage. *Vet. Parasitol.* 158:121–128.
263. Putignani L, et al. (2011). Investigation of *Toxoplasma gondii* presence in farmed shellfish by nested-PCR and real-time PCR fluorescent amplicon generation assay (FLAG). *Exp. Parasitol.* 127:409 – 417.
264. Rabaud C, et al. (1994). Extracerebral toxoplasmosis in patients infected with HIV. A French National Survey. *Medicine (Baltimore)* 73:306–314.
265. Rabaud C, et al. (1996). Pulmonary toxoplasmosis in patients infected with human immunodeficiency virus: a French National Survey. *Clin. Infect. Dis.* 23:1249 –1254.
266. Reese ML, Zeiner GM, Saeij JP, Boothroyd JC, Boyle JP. (2011). Polymorphic family of injected pseudokinases is paramount in *Toxoplasma* virulence. *Proc. Natl. Acad. Sci. U. S. A.* 108:9625–9630.
267. Remington JS. (1969). The present status of the IgM fluorescent antibody technique in the diagnosis of congenital toxoplasmosis. *J. Pediatr.* 75: 1116 – 1124.
268. Remington JS, Araujo FG, Desmonts G. (1985). Recognition of different *Toxoplasma* antigens by IgM and IgG antibodies in mothers and their congenitally infected newborns. *J. Infect. Dis.* 152:1020 –1024.
269. Remington JS, McLeod R, Thulliez P, Desmonts G. (2001). *Toxoplasmosis*, p 205–346. In Remington JS, Klein J (ed), *Infectious diseases of the fetus and newborn infant*, 5th ed. WB Saunders, Philadelphia, PA.
270. Renoult E, et al. (1997). Toxoplasmosis in kidney transplant recipients: report of six cases and review. *Clin. Infect. Dis.* 24:625– 634.
271. Rilling V, Dietz K, Krczal D, Knotek F, Enders G. (2003). Evaluation of a commercial IgG/IgM Western blot assay for early postnatal diagnosis of congenital toxoplasmosis. *Eur. J. Clin. Microbiol. Infect. Dis.* 22:174 – 180.
272. Robben PM, et al. (2004). Production of IL-12 by macrophages infected with *Toxoplasma gondii* depends on the parasite genotype. *J. Immunol.* 172:3686 –3694.
273. Robert F, et al. (1996). Retrospective evaluation of the detection of *Toxoplasma gondii* by polymerase chain reaction in AIDS patients. *Presse Med.* 25:541–545. (In French.)
274. Robert-Gangneux F, Commerce V, Tourteschaefer C, Dupouy-Camet J. (1999). Performance of a Western blot assay to compare mother and newborn anti-*Toxoplasma* antibodies for the early neonatal diagnosis of congenital toxoplasmosis. *Eur. J. Clin. Microbiol. Infect. Dis.* 18: 648 – 654.
275. Robert-Gangneux F, et al. (2010). Clinical relevance of placenta examination for the diagnosis of congenital toxoplasmosis. *Pediatr. Infect. Dis. J.* 29:33–38.
276. Robert-Gangneux F, et al. (2011). High level of soluble HLA-G in amniotic fluid is correlated with congenital transmission of *Toxoplasma gondii*. *Clin. Immunol.* 138:129 – 134.
277. Robert-Gangneux F, et al. (1999). Value of prenatal diagnosis and early postnatal diagnosis of congenital toxoplasmosis: retrospective study of 110 cases. *J. Clin. Microbiol.* 37:2893–2898.
278. Robert-Gangneux F, Yera H, D’Herve D, Guiguen C. (2009). Congenital toxoplasmosis after a preconceptional or periconceptional maternal infection. *Pediatr. Infect. Dis. J.* 28:660 – 661.
279. Robert-Gangneux F, et al. 2004. Usefulness of immunoblotting and Goldmann-Witmer coefficient for biological diagnosis of toxoplasmic retinochoroiditis. *Eur. J. Clin. Microbiol. Infect. Dis.* 23:34 –38.
280. Roberts F, et al. 2001. Histopathological features of ocular toxoplasmosis in the fetus and infant. *Arch. Ophthalmol.* 119:51–58.
281. Roemer E, et al. 2001. Toxoplasmosis, a severe complication in allogeneic hematopoietic stem cell transplantation: successful treatment strategies during a 5-year single-center experience. *Clin. Infect. Dis.* 32:E1–E8.
282. Rogers NM, et al. 2008. Transmission of toxoplasmosis in two renal allograft recipients receiving an organ from the same donor. *Transpl. Infect. Dis.* 10:71–74.
283. Romand S, et al. 2004. Usefulness of quantitative polymerase chain reaction in amniotic fluid as early prognostic marker of fetal infection with *Toxoplasma gondii*. *Am. J. Obstet. Gynecol.* 190:797–802.
284. Romand S, et al. 2001. Prenatal diagnosis using polymerase chain reaction on amniotic fluid for congenital toxoplasmosis. *Obstet. Gynecol.* 97:296 – 300.
285. Roos DS, et al. 1999. Origin, targeting, and function of the apicomplexan plastid. *Curr. Opin. Microbiol.* 2:426 – 432.
286. Rose AG, Uys CJ, Novitsky D, Cooper DK, Barnard CN. (1983). Toxoplasmosis of donor and recipient hearts after heterotopic cardiac transplantation. *Arch. Pathol. Lab. Med.* 107:368 – 373.
287. Roser D, Nielsen HV, Petersen E, Saugmann-Jensen P, Norgaard-Pedersen B. (2010). Congenital toxoplasmosis: a report on the Danish neonatal screening programme 1999–2007. *J. Inher. Metab. Dis.* 33: S241–S247.
288. Rynning FW, McLeod R, Maddox JC, Hunt S, Remington JS. (1979). Probable transmission of *Toxoplasma gondii* by organ transplantation. *Ann. Intern. Med.* 90:47– 49.

289. Saeij JP, Boyle JP, Boothroyd JC. (2005). Differences among the three major strains of *Toxoplasma gondii* and their specific interactions with the infected host. *Trends Parasitol.* 21:476 – 481.
290. Saeij JP, et al. (2006). Polymorphic secreted kinases are key virulence factors in toxoplasmosis. *Science* 314:1780 –1783.
291. Saeij JP, et al. (2007). *Toxoplasma* co-opts host gene expression by injection of a polymorphic kinase homologue. *Nature* 445:324 –327.
292. Salt A, et al. (1990). Viral and *Toxoplasma gondii* infections in children after liver transplantation. *J. Clin. Pathol.* 43:63– 67.
293. Sanchez Mejia A, Debrunner M, Cox E, Caldwell R. (2011). Acquired toxoplasmosis after orthotopic heart transplantation in a sulfonamide- allergic patient. *Pediatr. Cardiol.* 32:91– 93.
294. Sarchi E, et al. (2007). Surveillance of *Toxoplasma gondii* infection in recipients of thoracic solid organ transplants. *New Microbiol.* 30:299 – 302.
295. Savva D, Morris JC, Johnson JD, Holliman RE. (1990). Polymerase chain reaction for detection of *Toxoplasma gondii*. *J. Med. Microbiol.* 32:25–31.
296. Schmidt DR, et al. (2006). The national neonatal screening programme for congenital toxoplasmosis in Denmark: results from the initial four years, 1999-2002. *Arch. Dis. Child.* 91:661– 665.
297. Schoondermark-Van de Ven E, et al. (1993). Value of the polymerase chain reaction for the detection of *Toxoplasma gondii* in cerebrospinal fluid from patients with AIDS. *Clin. Infect. Dis.* 16:661– 666.
298. Schurmann D, et al. (2002). Effectiveness of twice-weekly pyrimethamine- sulfadoxine as primary prophylaxis of *Pneumocystis carinii* pneumonia and toxoplasmic encephalitis in patients with advanced HIV infection. *Eur. J. Clin. Microbiol. Infect. Dis.* 21:353–361.
299. Schwartzman J, et al. (1948). Congenital toxoplasmosis. *J. Pediatr.* 33:66 –73.
300. Shapiro K, et al. (2010). Detection of *Toxoplasma gondii* oocysts and surrogate microspheres in water using ultrafiltration and capsule filtration. *Water Res.* 44:893–903.
301. Sibley LD. (2010). How apicomplexan parasites move in and out of cells. *Curr. Opin. Biotechnol.* 21:592–598.
302. Sibley LD, Ajioka JW. (2008). Population structure of *Toxoplasma gondii*: clonal expansion driven by infrequent recombination and selective sweeps. *Annu. Rev. Microbiol.* 62:329 –351.
303. Sibley LD, Boothroyd JC. (1992). Virulent strains of *Toxoplasma gondii* comprise a single clonal lineage. *Nature* 359:82– 85.
304. Sickinger E, et al. (2008). Performance characteristics of the new ARCHITECT Toxo IgG and Toxo IgG Avidity assays. *Diagn. Microbiol. Infect. Dis.* 62:235–244.
305. Silveira C, et al. (2011). *Toxoplasma gondii* in the peripheral blood of patients with acute and chronic toxoplasmosis. *Br. J. Ophthalmol.* 95: 396 – 400.
306. Smith DD, Frenkel JK. (1995). Prevalence of antibodies to *Toxoplasma gondii* in wild mammals of Missouri and east central Kansas: biologic and ecologic considerations of transmission. *J. Wildl. Dis.* 31:15–21.
307. Sordet F, Aumjaud Y, Fessi H, Derouin F. (1998). Assessment of the activity of atovaquone- loaded nanocapsules in the treatment of acute and chronic murine toxoplasmosis. *Parasite* 5:223–229.
308. Sotiriadou I, Karanis P. (2008). Evaluation of loop-mediated isothermal amplification for detection of *Toxoplasma gondii* in water samples and comparative findings by polymerase chain reaction and immunofluorescence test (IFT). *Diagn. Microbiol. Infect. Dis.* 62:357– 365.
309. Sroka J, et al. (2010). The occurrence of *Toxoplasma gondii* infection in people and animals from rural environment of Lublin region estimate of potential role of water as a source of infection. *Ann. Agric. Environ. Med.* 17:125–132.
310. Sterkers Y, et al. (2010). Multicentric comparative analytical performance study for molecular detection of low amounts of *Toxoplasma gondii* from simulated specimens. *J. Clin. Microbiol.* 48:3216 –3222.
311. Stricker R, Sitavanc R, Liassine N, de Marval F. (2009). Toxoplasmosis during pregnancy and infancy. *Swiss Med. Wkly.* 139:643– 644.
312. Su C, et al. (2003). Recent expansion of *Toxoplasma* through enhanced oral transmission. *Science* 299:414 – 416.
313. Su C, Zhang X, Dubey JP. (2006). Genotyping of *Toxoplasma gondii* by multilocus PCR- RFLP markers: a high resolution and simple method for identification of parasites. *Int. J. Parasitol.* 36:841– 848.
314. Talabani H, et al. (2009). Contributions of immunoblotting, real-time PCR, and the Goldmann-Witmer coefficient to diagnosis of atypical toxoplasmic retinochoroiditis. *J. Clin. Microbiol.* 47:2131– 2135.
315. Taylor S, et al. (2006). A secreted serine-threonine kinase determines virulence in the eukaryotic pathogen *Toxoplasma gondii*. *Science* 314: 1776 –1780.
316. Tenter AM, Heckeroth AR, Weiss LM. (2000). *Toxoplasma gondii*: from animals to humans. *Int. J. Parasitol.* 30:1217–1258.
317. Thalib L, et al. (2005). Prediction of congenital toxoplasmosis by polymerase chain reaction analysis of amniotic fluid. *BJOG* 112:567– 574.
318. Thiebaut R, Leproust S, Chene G, Gilbert R. (2007). Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients' data. *Lancet* 369:115– 122.

319. Thulliez P. (2001). Efficacy of prenatal treatment for toxoplasmosis: a possibility that cannot be ruled out. *Int. J. Epidemiol.* 30:1315–1316.
320. Tissot-Dupont D, et al. (2003). Usefulness of Western blot in serological follow-up of newborns suspected of congenital toxoplasmosis. *Eur. J. Clin. Microbiol. Infect. Dis.* 22:122–125.
321. Turunen HJ, Leinikki PO, Saari KM. (1983). Demonstration of intraocular synthesis of immunoglobulin G *Toxoplasma* antibodies for specific diagnosis of toxoplasmic chorioretinitis by enzyme immunoassay. *J. Clin. Microbiol.* 17:988–992.
322. Unno A, et al. (2008). Dissemination of extracellular and intracellular *Toxoplasma gondii* tachyzoites in the blood flow. *Parasitol. Int.* 57:515–518.
323. Vaessen N, Verweij JJ, Spijkerman IJ, van Hoek B, van Lieshout L. (2007). Fatal disseminated toxoplasmosis after liver transplantation: improved and early diagnosis by PCR. *Neth. J. Med.* 65:222–223.
324. Vallochi AL, et al. (2005). The genotype of *Toxoplasma gondii* strains causing ocular toxoplasmosis in humans in Brazil. *Am. J. Ophthalmol.* 139:350–351.
325. Vasconcelos-Santos DV, et al. (2009). Congenital toxoplasmosis in south-eastern Brazil: results of early ophthalmologic examination of a large cohort of neonates. *Ophthalmology* 116:2199.e1–2205.e1.
326. Velmurugan GV, Dubey JP, Su C. (2008). Genotyping studies of *Toxoplasma gondii* isolates from Africa revealed that the archetypal clonal lineages predominate as in North America and Europe. *Vet. Parasitol.* 155:314–318.
327. Villard O, et al. (2003). Comparison of enzyme-linked immunosorbent assay, immunoblotting, and PCR for diagnosis of toxoplasmic chorioretinitis. *J. Clin. Microbiol.* 41:3537–3541.
328. Villena I, et al. (2010). Congenital toxoplasmosis in France in 2007: first results from a national surveillance system. *Euro Surveill.* 15(25): pii=19600. <http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19600>.
329. Villena I, et al. (2004). Evaluation of a strategy for *Toxoplasma gondii* oocyst detection in water. *Appl. Environ. Microbiol.* 70:4035–4039.
330. Vutova P, et al. (2007). *Toxoplasma gondii* inhibits Fas/CD95-triggered cell death by inducing aberrant processing and degradation of caspase 8. *Cell. Microbiol.* 9:1556–1570.
331. Waap H, Vilares A, Rebelo E, Gomes S, Angelo H. 2008. Epidemiological and genetic characterization of *Toxoplasma gondii* in urban pigeons from the area of Lisbon (Portugal). *Vet. Parasitol.* 157:306–309.
332. Wallon M, et al. (2010). Accuracy of real-time polymerase chain reaction for *Toxoplasma gondii* in amniotic fluid. *Obstet. Gynecol.* 115:727–733.
333. Wallon M, et al. (2004). Long-term ocular prognosis in 327 children with congenital toxoplasmosis. *Pediatrics* 113:1567–1572.
334. Wallon M, Liou C, Garner P, Peyron F. (1999). Congenital toxoplasmosis: systematic review of evidence of efficacy of treatment in pregnancy. *BMJ* 318:1511–1514.
335. Weiss LM, Kim K (ed). (2007). *Toxoplasma gondii: the model apicomplexan. Perspectives and methods.* Academic Press, London, United Kingdom.
336. Weiss LM, Dubey JP. (2009). Toxoplasmosis: a history of clinical observations. *Int. J. Parasitol.* 39:895–901.
337. Wendte JM, et al. (2010). Self-mating in the definitive host potentiates clonal outbreaks of the apicomplexan parasites *Sarcocystis neurona* and *Toxoplasma gondii*. *PLoS Genet.* 6:e1001261.
338. Westeneng AC, Rothova A, de Boer JH, de Groot-Mijnes JD. (2007). Infectious uveitis in immunocompromised patients and the diagnostic value of polymerase chain reaction and Goldmann-Witmer coefficient in aqueous analysis. *Am. J. Ophthalmol.* 144:781–785.
339. Wreghitt TG, et al. (1989). Toxoplasmosis in heart and heart and lung transplant recipients. *J. Clin. Pathol.* 42:194–199.
340. Yera H, et al. (2009). Multicenter comparative evaluation of five commercial methods for *Toxoplasma* DNA extraction from amniotic fluid. *J. Clin. Microbiol.* 47:3881–3886.
341. Zhou P, et al. (2010). Genetic characterization of *Toxoplasma gondii* isolates from pigs in China. *J. Parasitol.* 96:1027–1029.
342. Remington, J. S., Mcleod, R., Thulliez, P., & Desmonts, G. (2006). Toxoplasmosis. *Infectious Diseases of the Fetus and Newborn Infant*, 947-1091. doi: 10.1016/b0-72-160537-0/50033-5
343. Montoya, J. G., & Remington, J. S. (1995). Studies on the Serodiagnosis of Toxoplasmic Lymphadenitis. *Clinical Infectious Diseases*, 20(4), 781-789. doi:10.1093/clinids/20.4.781
344. Sabin, A. B., & Feldman, H. A. (1948). Dyes as Microchemical Indicators of a New Immunity Phenomenon Affecting a Protozoan Parasite (*Toxoplasma*). *Science*, 108(2815), 660-663. doi:10.1126/science.108.2815.660
345. Naot, Y., & Remington, J. S. (1981). Use of enzyme-linked immunosorbent assays (ELISA) for detection of monoclonal antibodies: Experience with antigens of *Toxoplasma gondii*. *Journal of Immunological Methods*, 43(3), 333-341. doi:10.1016/0022-1759(81)90181-2
346. Stepick-Biek, P., Thulliez, P., Araujo, F. G., & Remington, J. S. (1990). 19A Antibodies for Diagnosis of Acute Congenital and Acquired Toxoplasmosis. *Journal of Infectious Diseases*, 162(1), 270-273. doi:10.1093/infdis/162.1.270

347. Pinon J.M., Toubas D, Marx C, et al. (1990). Detection of specific immunoglobulin E in patients with toxoplasmosis. *J Clin Microbiol*, 28:1739–43.
348. Wong S.Y., Hadju M. P., Ramirez R, Thulliez P, McLeod R, Remington J.S. (1993). The role of specific immunoglobulin E in diagnosis of acute Toxoplasma infection and toxoplasmosis. *J Clin Microbiol*, 31:2952–9.
349. Dannemann B.R., Vaughan W. C., Thulliez P, Remington J. S. (1990). Differential agglutination test for diagnosis of recently acquired infection with Toxoplasma gondii. *J Clin Microbiol*, 28:1928–33.
350. Liesenfeld O, Montoya J.G., Tathineni N.J. et al., (2001). Confirmatory serologic testing for acute toxoplasmosis and rate of induced abortions among women reported to have positive Toxoplasma immunoglobulin M anti- body titers. *Am J Obstet Gynecol*, 184:140–5.
351. Montoya J.G., Remington J.S. (1996). Toxoplasmic chorioretinitis in the setting of acute acquired toxoplasmosis. *Clin Infect Dis*; 23:277–82.
352. Montoya J.G., Jordan R, Lingamneni S, Berry G.B., Remington J.S. (1997). Toxoplasmic myocarditis and polymyositis in patients with acute acquired toxoplasmosis diagnosed during life. *Clin Infect Dis*; 24:676–83.
353. Thulliez P, Remington J.S., Santoro F, Ovlaque G, Sharma S, Desmots G. (1986). A new agglutination test for the diagnosis of acute and chronic Toxoplasma infection. *Pathol Biol*; 34:173–7.
354. Hedman K, Lappalainen M, Seppala I, Makela O. (1989). Recent primary Toxoplasma infection indicated by a low avidity of specific IgG. *J Infect Dis*; 159:736–9.
355. Jenum P.A., Stray-Pedersen B, Gundersen A.G., (1997). Improved diagnosis of primary Toxoplasma gondii infection in early pregnancy by determination of antitoxoplasma immunoglobulin G activity. *J Clin Microbiol*; 35:1972–7.
356. Liesenfeld O, Montoya JG, Kinney S, (2001). Press C, Remington JS. Effect of testing for IgG avidity in the diagnosis of Toxoplasma gondii infection in pregnant women: experience in a US reference laboratory. *J Infect Dis*; 183:1248–53.
357. Liesenfeld O, Press C, Montoya J.G., et al., (1997). False-positive results in immunoglobulin M (IgM) Toxoplasma antibody tests and importance of confirmatory testing: the Platelia toxo IgM test. *J Clin Microbiol*; 35:174–8.
358. Wilson M, Remington J.S., Clavet C, Varney G, Press C, Ware D, (1997). Group TFTAHW. Evaluation of six commercial kits for detection of human immunoglobulin M antibodies to Toxoplasma gondii. *J Clin Microbiol*; 35:3112–5.
359. Bobic B, Sibalic D, Djurkovic-Djakovic O. (1991). High levels of IgM antibodies specific for Toxoplasma gondii in pregnancy 12 years after primary toxoplasma infection. *Gynecol Obstet Invest*; 31:182–4.
360. Grover C.M., Thulliez P, Remington J.S., Boothroyd J.D., (1990). Rapid prenatal diagnosis of congenital Toxoplasma infection by using polymerase chain reaction and amniotic fluid. *J Clin Microbiol*; 28:2297–2301.
361. Johnson M.W., Greven C.M., Jaffe G.J., Sudhalkar H, Vine A.K., (1997). Atypical, severe toxoplasmic retinochoroiditis in elderly patients. *Ophthalmology*; 104:48–57.
362. Montoya J.G., Parmley S, Liesenfeld O, Jaffe G.J., Remington J.S., (1999). Use of the polymerase chain reaction for diagnosis of ocular toxoplasmosis. *Ophthalmology*; 106:1554–63.
363. Brezin A.P., Egwuagu C.E., Burnier M, et al. (1990). Identification of Toxoplasma gondii in paraffin-embedded sections by the polymerase chain reaction. *Am J Ophthalmol*; 110:599–604.
364. Dupouy-Camet J, Lavareda de Souza L, Maslo C, et al. (1993). Detection of Toxoplasma gondii in venous blood from AIDS patients by polymerase chain reaction. *J Clin Microbiol*; 31:1866–9.
365. Holliman R.E., Johnson J.D., Savva D. (1990). Diagnosis of cerebral toxoplasmosis in association with AIDS using the polymerase chain reaction. *Scand J Infect Dis*; 22:243–4.
366. Parmley S.F., Goebel F.D., Remington J.S., (1992) Detection of Toxoplasma gondii DNA in cerebrospinal fluid from AIDS patients by polymerase chain reaction. *J Clin Microbiol*; 30:3000–2.
367. Roth A, Roth B, Hoffken G, Zablocki P, Steuber S, Janitschke K. (1992). Application of the polymerase chain reaction to diagnosis of pulmonary toxoplasmosis in immunocompromised patients. *Eur J Clin Microbiol Infect Dis*; 11:1177–81.
368. Conley F.K., Jenkins K.A., Remington J.S., (1981). Toxoplasma gondii infection of the central nervous system. Use of the peroxidase-antiperoxidase method to demonstrate Toxoplasma in formalin fixed, paraffin embedded tissue sections. *Hum Pathol*; 12:690–8.
369. Liesenfeld O, Press C, Flanders R, Ramirez R, Remington J.S., (1996). Study of Abbott toxo IMx system for detection of immunoglobulin G and immunoglobulin M Toxoplasma antibodies: value of confirmatory testing for diagnosis of acute toxoplasmosis. *J Clin Microbiol*; 34:2526–30.
370. Remington J.S., (1974). Toxoplasmosis in the adult. *Bull N Y Acad Med*; 50:211–27.
371. Montoya J.G., Remington J.S., (2000). Toxoplasma gondii. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. Philadelphia: Churchill Livingstone,; 2858–88.
372. Dorfman R.F., Remington J.S., (1973). Value of lymph-node biopsy in the diagnosis of acute acquired toxoplasmosis. *N Engl J Med*; 289: 878–81.

373. Silveira C, Belfort R Jr, Burnier M Jr, Nussenblatt R. (1988). Acquired toxoplasmic infection as the cause of toxoplasmic retinochoroiditis in families. *Am J Ophthalmol*; 106:362–4.
374. Couvreur J, Thulliez P. (1996). Toxoplasmose acquise à localisation oculaire ou neurologique. [Acquired toxoplasmosis of ocular or neurologic site: 49 cases.] *Presse Med*; 25:438–42.
375. Holland G.N., O'Connor G.R., Belfort R Jr, Remington J.S., (1996). Toxoplasmosis. In: Pepose JS, Holland GN, Wilhelmus KR, eds. Ocular infection and immunity. *St. Louis: Mosby Yearbook*: 1183–223.
376. Diaz M.G., Miller D, Perez E, Rosa R.H., Davis J.L., Alfonso EC., (1997). Recovery and identification of *Toxoplasma gondii* in cell culture as a causative agent of necrotizing retinitis [abstract C-483]. In: Proceedings of the 97th annual meeting of the American Society for Microbiology (Miami Beach, FL, 4–8 May). Washington, DC: ASM,.
377. Israelski D.M., Remington J.S., (1993). Toxoplasmosis in the non-AIDS immunocompromised host. *Curr Clin Top Infect Dis*; 13:322–56.
378. Luft B.J., Remington J.S., (1992). Toxoplasmic encephalitis in AIDS. *Clin Infect Dis*; 15:211–22.
379. Montoya J.G., Remington J.S., (1997). Toxoplasmosis of the central nervous system. In: Peterson PK, Remington JS, eds. In: Defense of the brain: current concepts in the immunopathogenesis and clinical aspects of CNS infections. Boston: *Blackwell Scientific*;:163–88.
380. Liesenfeld O, Wong S.Y., (1999). Remington JS. Toxoplasmosis in the setting of AIDS. In: Bartlett JG, Merigan TC, Bolognesi D, eds. Textbook of AIDS medicine. 2d ed. *Baltimore: Williams & Wilkins*;:225–9.
381. Derouin F, Gluckman E, Beauvais B, et al., (1986). Toxoplasma infection after human allogeneic bone marrow transplantation: clinical and serological study of 80 patients. *Bone Marrow Transplant*; 1:67–73.
382. Luft B.J., Naot Y, Araujo F.G., Stinson E.B., Remington JS., (1983). Primary and re-activated Toxoplasma infection in patients with cardiac transplants. Clinical spectrum and problems in diagnosis in a defined population. *Ann Intern Med*; 99:27–31.
383. Luft B.J., Billingham M, Remington J.S., (1986). Endomyocardial biopsy in the diagnosis of toxoplasmic myocarditis. *Transplant Proc*; 18:1871–3.
384. Hohlfeld P, Daffos F, Costa J.M., Thulliez P, Forestier F, Vidaud M. (1994). Prenatal diagnosis of congenital toxoplasmosis with a polymerase chain reaction test on amniotic fluid. *N Engl J Med*; 331:695–9.
385. Romand S, Wallon M, Franck J, Thulliez P, Peyron F, Dumon H. (2001). Prenatal diagnosis using polymerase chain reaction on amniotic fluid for congenital toxoplasmosis. *Obstet Gynecol*; 97:296–300.
386. Krahenbuhl J.L., Gaines J.D., Remington J.S., (1972). Lymphocyte transformation in human toxoplasmosis. *J Infect Dis*; 125:283–8.
387. Wilson C.B., Desmonts G, Couvreur J, Remington J.S., (1980). Lymphocyte transformation in the diagnosis of congenital Toxoplasma infection. *N Engl J Med* 302:785–8.
388. McLeod R, Mack D.G., Boyer K, et al., (1990). Phenotypes and functions of lymphocytes in congenital toxoplasmosis. *J Lab Clin Med* 116: 623–35.